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Abstract 
Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen 
cycloaddition to afford a novel family of N1- and C5-substituted 1,2,3-triazole 
derivatives that feature the propargylamine group typical of irreversible MAO-B 
inhibitors at the C4-side chain of the triazole ring. All the synthesized compounds were 
evaluated against human MAO-A and MAO-B. Structure‒activity relationships and 
molecular modelling were utilized to gain insight into the structural and chemical 
features that enhance the binding affinity and selectivity between the two enzyme 
isoforms. Several lead compounds, in terms of potency (submicromolar to low 
micromolar range), MAO-B selective recognition, and brain permeability, were 
identified. One of these leads (MAO-B IC50 of 3.54 μM, selectivity MAO-B/MAO-A 
index of 0.036) was further subjected to reversibility and time-dependence inhibition 
studies, which disclosed a slow and irreversible inhibition of human MAO-B. Overall, 
the results support the suitability of the 4-triazolylalkyl propargylamine scaffold for 
exploring the design of multipotent anti-Alzheimer compounds endowed with 
irreversible MAO-B inhibitory activity. 
 
Keywords 
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1. Introduction 
Alzheimer’s disease (AD) is one of the most relevant age-related neurodegenerative 
disorders currently representing the fourth leading cause of death and afflicting over 
46.8 million people worldwide.1,2 Its clinical manifestation is mainly reflected in a 
progressive loss of memory and cognitive functions, often in association with 
behavioral disturbances and depression.3 Its complex and multifaceted etiopathology, 
which involves massive loss of cholinergic neurons,4 oxidative stress,5-7 metal 
dyshomeostasis,8 excitotoxicity,9 neurofibrillary tangles and β-amyloid aggregate 
deposition,10,11 has precluded so far the discovery of effective disease-modifying drugs. 
Currently approved drugs, namely, three acetylcholinesterase (AChE) inhibitors 
(rivastigmine, galantamine, and donepezil),12-14 and an N-methyl-D-aspartate receptor 
antagonist (memantine),15 primarily exert palliative effects. On the other hand, the 
failure in clinical trials of a number of drug candidates designed against targets mainly 
involved in β-amyloid biology has shifted drug discovery efforts toward the compounds 
hitting less explored biological targets alone or in combination with other key targets, 
i.e. the so-called multi-target-directed ligands (MTDLs).16-18 
In this context, monoamine oxidase (MAO, E.C.1.4.3.4) has emerged as a promising 
target because of the neuroprotective properties exerted by their inhibitors.2,19-21 MAO 
is a flavin adenine dinucleotide (FAD)-containing enzyme that catalyzes the 
degradation of biogenic and xenobiotic amines. Two isoforms, namely MAO-A and 
MAO-B, have been characterized by their amino acid sequence, tissue distribution, 
substrate specificity and inhibitor sensitivity.22-24 MAO-A, preferentially degrading 
serotonin, adrenaline and noradrenaline, is irreversibly inhibited by clorgyline, whereas 
MAO-B, specifically responsible for the oxidative deamination of phenylethylamine 
and benzylamine, is irreversibly inhibited by (R)-(−)-deprenyl (selegiline)  (Figure 1). 
These trends reflect structural differences in the binding sites as revealed by high-
resolution X-ray structures.25-29 In particular, a key structural feature in shaping the 
substrate cavity is the replacement of the pair Phe208/Ile335 in MAO-A by 
Ile199/Tyr326 in MAO-B, leading to the distinction between “substrate” and “entrance” 
sites in MAO-B. The replacement of Ile180/Asn181 and Val210 in MAO-A by 
Leu17/Cys172 and Thr201 in MAO-B are additional differences in the binding sites, 
which may modulate the selective inhibition by certain MAO inhibitors.30 
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Figure 1. Chemical structures of MAO inhibitors. 
 
The neuroprotection exerted by MAO inhibitors may stem not only from the increased 
amine neurotransmission, but also from preventing the formation of neurotoxic species, 
which may lead to neuronal damage,31,32 and from the anti-apoptotic properties of the 
propargylamine group present in some MAO inhibitors.33,34 Interestingly, the levels of 
MAO-B increase with age and its activity is elevated in AD patients, which results in 
increased brain levels of neurotoxic free radicals.20 In this context, the development of 
MAO-B-inhibitor-based MTDLs emerges as a promising strategy for the design of 
neuroprotective agents with potential disease-modifying activity towards AD and other 
neurodegenerative disorders, such as Parkinson disease.35,36  
Most efforts have been addressed toward the design of MTDLs targeting AChE and/or 
butyrylcholinesterase (BuChE) and MAO. A successful example is ladostigil (Figure 1), 
a dual inhibitor of MAO-B and AChE that combines the carbamate moiety of the AChE 
inhibitor rivastigmine with the indolamine moiety of the selective MAO-B inhibitor 
rasagiline, and shows neuroprotective and anti-apoptotic activities.37,38 A novel series of 
MAO/ChE inhibitors that combine the N-benzylpiperidine moiety of the AChE inhibitor 
donepezil with the indolyl propargylamine of the potent MAO-B inhibitor PF9601N has 
been reported.39 Within this series, the most promising MDTL compound (ASS234, 6 in 
Figure 1) also showed anti-aggregating activity on E-amyloid, antioxidant and 
antiapoptotic behaviour, and crossed easily the blood-brain barrier (BBB).40 Other 
strategies have relied on the hybridization of coumarins with either N-benzyl-N-
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alkyloxy groups41 or tacrine,42 leading to multipotent inhibitors of both MAO and ChEs, 
or alternatively have pursued the development of MTDLs targeting both MAO 
inhibition and additional activities, such as metal chelation.43,44 Also, natural products 
endowed with MAO and ChEs inhibitory activities have been recently reported.45 
Although the development of MAO-inhibitor-based MTDLs is very attractive, it is 
challenged by the need to keep a good balance among potencies against multiple targets 
and optimal ADME-T properties.46-50 Furthermore, the success of this strategy depends 
on the suitability of an efficient synthetic approach, which should afford the fusion or 
linkage of chemical scaffolds while minimizing drastic alterations in the activity against 
the multiple targets. In this context, the Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) enables the synthesis of a virtually unlimited source of ligands containing the 
1,4-disubstituted 1,2,3-triazole core.51-54 The CuAAC reaction between libraries of 
azides and alkynes featuring different pharmacophoric moieties has been used for the 
synthesis of triazole-linked hybrid compounds as MTDLs.55-65 Azide-alkyne 
cycloaddition reactions have also been used for the synthesis of high-affinity multisite 
enzyme inhibitors inside the biological target, in the absence of copper catalysis, i.e. the 
so-called in situ click chemistry.66-70  In these compounds the triazole ring is used not 
only as a non-hydrolyzable, non-oxidizable, and non-reducible robust linker between 
the pharmacophoric moieties, but also provides favourable physicochemical properties 
and potential interactions with the biological target.71 
In this context, as the first step of a program directed to the synthesis of MAO-B-
inhibitor-based anti-Alzheimer MTDLs, here we have explored the CuAAC-mediated 
synthesis of a series of 1,2,3-triazole derivatives, featuring the propargylamine group of 
typical irreversible MAO-B inhibitors in the side chain at position 4, while the overall 
hydrophobicity has been modulated through different lipophilic substituents at positions 
1 and 5 (Scheme 1). To determine the therapeutic potential of the target compounds and 
their usefulness as the MAO-B pharmacophoric moiety of novel families of MTDLs, we 
have assessed the in vitro inhibitory activity of the novel compounds against human 
MAO-B and MAO-A. Molecular modelling studies have been performed to rationalize 
the differences in inhibitory potency and selectivity between the MAO isoforms, and the 
mechanism of action of these compounds has been studied by reversibility and time-
dependence inhibition studies. Finally, the brain penetration of the novel compounds 
has been examined through the widely used parallel artificial membrane permeability 
assay (PAMPA-BBB). 
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Scheme 1. General structure of the target N-methyl-N-[(1,2,3-triazol-4-
yl)alkyl]propargylamines. 
 
 
2. Results and Discussion 
2.1. Design and synthesis of the target N-methyl-N-[(1,2,3-triazol-4-
yl)alkyl]propargylamines 
We initially planned the synthesis of the 1-ethyltriazolylmethyl and 1-ethyltriazolylethyl 
propargylamines 31 and 32 (Scheme 2), unsubstituted at position 5 of the triazole ring, 
and their 5-methyl-substituted analogues 51 and 52, as the early simple prototypes to 
validate the suitability of the CuAAC-assisted synthetic methodology to deliver 1,4-
disubstituted and 1,4,5-trisubstituted 1,2,3-triazole scaffolds featuring the 
propargylamine group of irreversible MAO inhibitors. These compounds are quite polar 
(LogP of 0.43, 0.84, 0.65, and 1.06, respectively)72 due to the presence of the triazole 
ring. However, the substrate cavity of MAO is highly hydrophobic, and accordingly 
MAO inhibitors are usually more lipophilic molecules (LogP in the range 2-4 for 
compounds depicted in Figure 1). Thus, to counterbalance the high polarity conferred 
by the triazole ring, we envisaged a second generation of derivatives that featured more 
lipophilic benzyl or phenethyl substituents at position 1 (i.e. compounds 33 and 34, 
respectively, Scheme 2) or at position 5 of the triazole ring (i.e. the 1-methyl-5-butyl-
substituted compound 54). We also planned the synthesis of derivatives of the 1-benzyl-
substituted compound 33 bearing different alkyl groups at position 5. However, the 
moderate acidity of the α-nitrogen benzylic protons of the substituent at position 1 of 
the triazole ring interfered with the alkylation of the position 5 (see below). To avoid 
these synthetic issues, we envisaged the synthesis of compounds 55, 56, and 57 
(Scheme 2), bearing a phenyl group instead of a benzyl group at position 1 of the 
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triazole ring and ethyl, propyl, or butyl substituents at position 5. Finally, we also 
explored the isomerization of the benzene ring of compound 33 from the substituent at 
position 1 of the triazole ring to the side chain at position 4, i.e. between the triazole 
ring and the propargylamine moiety (compounds 82 and 83, Scheme 3). 
After evaluation of MAO-A and MAO-B inhibitory activity of the first and second 
generation compounds, 33 emerged as the most selective MAO-B inhibitor, with a one-
digit micromolar potency against MAO-B, 27-fold higher than against MAO-A, 
whereas compound 83 turned out to be the most potent inhibitor of both MAO isoforms, 
with submicromolar potencies but essentially without any selectivity (see below). In 
light of these results and on the basis of molecular modelling studies, we inferred that a 
total number of three methylenes might afford the optimal length between the terminal 
aromatic ring and the propargylamine nitrogen atom to confer selectivity towards 
MAO-B. To check this hypothesis, as a third generation we planned the synthesis of 
compound 36 (Scheme 2), an isomeric derivative of 33, and compound 84 (Scheme 3), 
with a total number of three methylenes from the terminal aromatic ring (phenyl in 36, 
triazole in 84) to the propargylamine nitrogen atom. For comparison purposes, we also 
envisaged the synthesis of compound 35 (Scheme 2), the shorter homologue of 33 with 
a total number of two methylenes in the tether. 
The synthesis of the target compounds was undertaken through synthetic sequences 
involving as the key step a CuAAC reaction73-76 between alkyl or phenyl azides and 
alkynes bearing an amino or a cyano group to enable the subsequent installation of the 
propargylamine moiety (Scheme 1). The synthesis of the 5-unsubstituted 
triazolylmethyl and triazolylethyl propargylamines 31‒36 was carried out through a 
four-step synthetic sequence, starting from the copper-catalyzed Huisgen 1,3-dipolar 
cycloaddition of the known N-Boc-protected amines 7 and 8 with ethyl, benzyl, and 
phenethyl azide, generated in situ by reaction of NaN3 with the corresponding alkyl 
halide,77 which afforded the 1-substituted triazole derivatives 9‒16 in moderate to good 
yields (49-78%, Scheme 2). Subsequent methylation of the N-Boc-protected aliphatic 
nitrogen atom of compounds 9‒16 with MeI in anhydrous THF, in the presence of NaH, 
followed by acidic deprotection of the resulting compounds 17‒24 afforded the 
secondary amines 25‒30 in general in excellent yields. The final propargylation of 
amines 25‒30 on reaction with propargyl bromide in acetone in the presence of Cs2CO3 
led to propargylamines 31‒36 in 22‒89% yield (Scheme 2). Thus, the target compounds 
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31‒36 were obtained in 5‒58% overall yield without the need of any column 
chromatography purification, with the sole exception of the last step for 31, 35 and 36. 
 
 
 
Scheme 2. Reagents and conditions: (i) CuSO4·5H2O, ascorbic acid, Na2CO3, 
H2O/DMF, rt, overnight, 49‒78% yield; (ii) MeI, NaH, THF, rt, 1.5‒15 h, 81‒97% 
yield; (iii) H3PO4, CH2Cl2, rt, 1.5‒4 h, 38‒98% (25‒30), 67‒100% (44‒50); (iv) 
propargyl bromide, Cs2CO3, acetone, rt for 2‒15 h, or 0 ºC for 2‒2.5 h, or 0 ºC for 30 
min and then rt for 3 h, 22‒89% (31‒36), 53‒95% (51‒57); (v) R5-Hal, n-BuLi, THF, 
‒78 ºC, 1 h, then ‒78 ºC → rt, and rt, 2 h, 43‒98%. 
 
 
For the synthesis of the 5-alkyl-substituted triazolylmethyl and triazolylethyl 
propargylamines 51, 52, and 54, apart from the intermediates 17 and 18, the triazole 
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derivative 21 was also prepared in good yield using the same CuAAC-N-methylation 
protocol (Scheme 2). Alkylation of compounds 17, 18, and 21 with the appropriate alkyl 
halide using n-BuLi as the base afforded the corresponding 5-alkylated compounds 37, 
38, and 40, respectively, in excellent yields (90‒97%). However, when we subjected the 
1-benzyl-substituted intermediate 19 to the same alkylation reaction conditions with 
methyl iodide as the alkylating agent, we did not obtain the expected 1-benzyl-5-
methyl-substituted derivative but the 1-(α-methylbenzyl)-5-methyl-substituted 
derivative 39 in 79% yield, resulting from the double alkylation at the position 5 of the 
triazole ring and at the moderately acidic α-nitrogen benzylic position of the substituent 
at position 1 (Scheme 2). Treatment of intermediate 19 with ethyl bromide or n-butyl 
bromide as the alkylating agents and n-BuLi or the more hindered t-BuLi as the base 
yielded inseparable mixtures of 5-monoalkylated and α,5-dialkylated products. To avoid 
double alkylation, we prepared the 1-phenyl-substituted intermediate 22, which was 
alkylated with ethyl bromide, n-propyl bromide, and n-butyl bromide using n-BuLi as 
the base, to afford the expected 5-alkyl-substituted derivatives 41, 42, and 43 in 98%, 
96%, and 43% yield, respectively (Scheme 2). The acidic N-Boc deprotection of 5-
alkyl-substituted compounds 37‒43 afforded the secondary amines 44‒50 in good 
yields (67% to quantitative yield). Propargylation of amines 44‒50 had to be performed 
by monitoring the reaction course at different reaction temperatures and times to avoid 
the formation of dipropargylated products. For example, reaction of amine 44 with 
propargyl bromide in the presence of Cs2CO3 at rt overnight yielded the dipropargylated 
derivative as the major reaction product (92% yield), whereas on reaction at 0 ºC for 2 h 
only the desired monopropargylated product, 51, was obtained, in 62% yield. Thus, by 
selecting the most appropriate reaction temperature and time, the target 5-alkyl-
substituted triazolylmethyl and triazolylethyl propargylamines 51‒57 were synthesized 
(19‒44% overall yield over the five-step sequence). 
The synthesis of the triazolyl-m-xylyl and triazolyl-p-xylyl propargylamines 82 and 83 
and the triazolyl-p-methylphenethyl propargylamine 84 was carried out through the 
seven‒eight-step sequences depicted in Scheme 3. First, the alkynes 64‒66, necessary 
for the CuAAC, were prepared by an initial Negishi coupling77 between benzyl 
bromides 58‒60 and trimethylsilylacetylene in the presence of n-BuLi and ZnBr2, under 
Pd(0) catalysis, followed by desilylation of the protected alkyne derivatives 61‒63 with 
AgOTf in a mixture of CH2Cl2/MeOH/H2O,78 and silica gel column chromatography 
purification. The CuAAC of methyl azide to alkynes 64‒66 afforded the corresponding 
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triazole derivatives 67‒69 in excellent yield (89‒95%). LiAlH4 reduction of the nitrile 
group of 67 and 68 afforded the corresponding amines 70 and 71 in 49% and 80% yield, 
respectively. However, the same reaction conditions failed to provide the amine derived 
from nitrile 69, which could be efficiently reduced to amine 72 by hydrogenation using 
Raney-Ni as the catalyst. N-Boc protection of the primary amino group of 70‒72   
afforded the intermediates 73‒75. The N-Boc-protected amines 73 and 74 were 
converted into the target propargylamines 82 and 83 in good yields through the standard 
N-methylation‒acidic deprotection‒propargylation protocol, without the need of any 
additional column chromatography purification (Scheme 3). Because different attempts 
to methylate the N-Boc-protected amine 75 were fruitless, this compound was 
alternatively converted into the target propargylamine 84 by direct conversion into the 
secondary amine 81 upon LiAlH4 reduction followed by progargylation (Scheme 3). 
All the compounds to be subjected to biological evaluation were transformed into the 
corresponding hydrochloride salts and were chemically characterized through IR, 1H 
and 13C NMR spectra, and HRMS. 
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Scheme 3. Reagents and conditions: (i) trimethylsilylacetylene, THF, n-BuLi, ‒78 ºC, 
30 min, then, ZnBr2, THF, ‒78 ºC → 0 ºC, then, 58, 59, or 60, Cl2Pd(PPh3)2, rt, 
overnight, 44‒83% yield; (ii) AgOTf, CH2Cl2/MeOH/H2O, rt, overnight, 63‒77% yield; 
(iii) CuSO4·5H2O, ascorbic acid, Na2CO3, H2O/DMF, rt, overnight, 89‒95% yield; (iv) 
LiAlH4, THF, reflux, 2 h: 70 (49%), 71 (80%), or H2, Raney-Ni, 7 N NH3 in MeOH: 72 
(quantitative); (v) (Boc)2O, THF, rt, 3 h, quantitative yield; (vi) MeI, NaH, THF, 60 ºC, 
4 h: 76 (84%), 77 (80%); (vii) LiAlH4, THF, 0 ºC, then 75, reflux, 72 h: 81 (44% yield); 
(viii) H3PO4, CH2Cl2, rt, 1.5‒3 h: 79 (quantitative), 80 (96%); (ix) propargyl bromide, 
Cs2CO3, acetone, 0 ºC for 3.5 h or 0 ºC for 30 min and then rt for 3 h, 31‒65% yield. 
 
 
2.2. MAO inhibitory activity of the target compounds 
The novel N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines 31‒36, 51‒57, and 
82‒84 were evaluated in vitro against human recombinant MAO-A and MAO-B 
(hrMAO-A and hrMAO-B). Selegiline and clorgyline were also used as reference 
compounds. The corresponding IC50 values and selectivity indices (SI; defined as the 
ratio IC50(MAO-B)/IC50(MAO-A)) are shown in Table 1. The novel compounds turned 
out to be in most cases moderate to weak MAO inhibitors, with 2‒3-digit micromolar 
IC50 values, with the exceptions of compounds 33, 55, 82 and 83, which exhibited 
submicromolar or low micromolar potencies against one or both MAO isoforms. 
The first generation compounds 31, 32, 51, and 52 were weak inhibitors and showed no 
selectivity. These trends were not unexpected due to the large polarity of the triazole 
ring and the small size of these fragment-like compounds. Accordingly, several 
strategies were explored to modulate both the molecular size and hydrophobicity of the 
triazole derivatives. The first approach involved the substitution of the ethyl group at 
position 1 of the triazole ring of the initial prototypes by benzyl and phenethyl groups, 
which led to increased inhibitory potencies. Thus, the 1-phenethyl-derivative 34 was 2- 
and 10-fold more potent MAO-A inhibitor than the 1-benzyl- and 1-ethyl-analogues 33 
and 32, respectively. In contrast, for MAO-B inhibition, the optimal substitution pattern 
involved the presence of a 1-benzyl group, with compound 33 being 49- and 106-fold 
more potent than the 1-phenethyl- and 1-ethyl-analogues 34 and 32, respectively.  
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Table 1. MAO-A and MAO-B inhibitory activities, selectivity indices, and BBB 
permeability. 
Compound hrMAO-Aa 
IC50 (µM) 
hrMAO-Ba 
IC50 (µM) 
SIb Pe (10–6 cm s–1)c 
1st generation 
31 134.7 ± 21.8 248.6 ± 94.5 1.8 ndd 
32 553.5 ± 83.6 373.9 ± 119 0.7 ndd 
51 267.4 ± 30.8 104.7 ± 27.1 0.4 ndd 
52 91.2 ± 13.6 237.6 ± 51.8 2.6 ndd 
2nd generation 
33 97.1 ± 30.1 3.54 ± 0.44 0.036 15.6 ± 1.5 (CNS+) 
34 56.1 ± 8.7 172.8 ± 47.8 3.1 14.8 ± 0.9 (CNS+) 
53 47.0 ± 6.9 134.2 ± 25.5 2.9 20.0 ± 0.7 (CNS+) 
54 < 300 94.73 ± 16.3 < 0.32 29.9 ± 0.8 (CNS+) 
55 7.5 ± 1.1 213.4 ± 54.0 28.5 17.0 ± 1.9 (CNS+) 
56 26.1 ± 4.0 156.8 ± 31.9 6.0 17.2 ± 0.6 (CNS+) 
57 17.3 ± 4.5 155.5 ± 25.0 9.0 21.4 ± 1.3 (CNS+) 
82 2.12 ± 0.32 64.96 ± 15.4 30.6 15.6 ± 1.5 (CNS+) 
83 0.53 ± 0.06 0.60 ± 0.08 1.15 14.8 ± 0.9 (CNS+) 
3rd generation 
35 > 500 129 ± 42.6 < 0.26 2.3 ± 0.7 (CNS+/-) 
36 > 500 11.2 ± 2.1 < 0.022 0.6 ± 0.1 (CNS-) 
84 27.4 ± 0.1 5.22 ± 0.49 0.19 4.5 ± 0.5 (CNS+/-) 
Selegiline 
Clorgyline 
2 ± 0.1 
0.020 ± 0.003 
0.018 ± 0.003 
ndd 
0.009  
a In vitro inhibitory activities against hr-MAO-A and hr-MAO-B. Experiments 
performed with Amplex Red fluorimetric method in 96-well plates. Data are the mean 
of duplicate experiments ± SEM. 
b SI = IC50 (MAO-B) / IC50 (MAO-A). 
c Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± 
SD of three independent experiments. 
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d Not determined. 
 
This latter finding suggests that the size of compound 33 is better suited to fill the 
binding cavity in MAO-B, as confirmed by the results obtained from restrained docking 
calculations. Thus, following the strategy used in our previous studies,39 the 
propargylamine nitrogen atom was imposed to overly the position of the corresponding 
atom in the X-ray structures of covalently-bound selegiline and rasagiline (PDB entries 
2BYB and 2BK4).28,79 By imposing this restraint, we may explore the arrangement of 
the compound after covalent linkage of the propargylamine unit to the FAD cofactor. 
Figure 2 shows that 33 superposes well with the structures of the irreversible inhibitor 6 
(PDB entry 4CRT),80 and the reversible ligand 1,4-diphenyl-2-butene (PDB entry 
1OJ9),26 which spans the substrate binding cavity. In particular, it is worth noting that 
the benzene ring of 33 matches well the position filled by the benzene unit in 1,4-
diphenyl-2-butene. In turn, docking of the phenethyl derivative 34 made it necessary to 
adopt a folded conformation, reflecting some degree of internal strain due to clashes 
within the cavity (data not shown). 
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Figure 2. Representation of the docked pose of compound 33 (shown as green-coloured 
sticks) in the binding cavity of MAO-B (shown as gray cartoon). The surface of the 
binding cavity is depicted as a gray isocontour. The structures of inhibitor 6 (PDB entry 
4CRT; covalently-bound to FAD, also shown as gray-coloured sticks) and the reversible 
ligand 1,4-diphenyl-2-butene (PDB entry 1OJ9) are shown as white-colored and yellow 
sticks, respectively.  
 
 
An alternative strategy explored to modulate the hydrophobicity distribution of triazole 
derivatives relied on the alkylation of position 5 of the triazole ring (compounds 53‒57). 
However, alkylation did not seem to have a clear effect on MAO inhibitory potency, 
although this chemical modification was generally beneficial for MAO-A selectivity for 
compounds bearing large substituents at position 1 (Ph-CH(Me)- or Ph), with selectivity 
indices in the range 2.9‒28.5 (compounds 53, 55-57 in Table 1). 
Finally, we also envisaged the isomerization of the benzene ring of compound 33 from 
the substituent at position 1 of the triazole ring to the side chain at position 4. This 
approach led to increased MAO-A inhibitory potencies, with compounds 82 and 83 
being 46- and 183-fold more potent than 33, and also to increased MAO-B inhibitory 
activity in the case of 83 (6-fold more potent than 33), bearing a para-disubstituted 
benzene ring in the side chain at position 4. Docking calculations of compound 83 also 
led to a binding pose that filled the binding cavity of MAO-B (Figure 3), while docking 
of the derivative with a meta-disubstituted benzene (compound 82) revealed steric 
clashes in the substrate binding cavity (data not shown), in agreement with the 100-fold 
ratio in the IC50 values determined for these compounds against hrMAO-B (Table 1). 
In agreement with the hypothesis that a total number of three methylenes separating the 
terminal aromatic ring and the propargylamine nitrogen atom afforded the optimal 
length to confer selectivity towards MAO-B, third generation compounds 36 and 84 
turned out to be selective for MAO-B versus MAO-A inhibition, with IC50 values for 
MAO-B inhibition in the low micromolar range. Compound 36 was found to be more 
selective MAO-B inhibitor than its shorter homologue 35, and even more selective than 
its isomer 33 with the same total number of methylenes in the tether (27-fold more 
potent for MAO-B than for MAO-A inhibition; Table 1). Also, in contrast with 
compounds 82 and 83, with the inverse selectivity or with no selectivity, compound 84 
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was found to be 5-fold more potent for MAO-B than for MAO-A inhibition, albeit with 
a 9-fold lower potency than its shorter homologue 83. 
 
 
 
Figure 3. Representation of the docked pose of compound 83 (shown as green-coloured 
sticks) in the binding cavity of MAO-B (shown as gray cartoon). The surface of the 
binding cavity is depicted as a gray isocontour. The structures of inhibitor 6 (PDB entry 
4CRT; covalently-bound to FAD, also shown as gray-coloured sticks) and the reversible 
ligand 1,4-diphenyl-2-butene (PDB entry 1OJ9) are shown as white-colored and yellow 
sticks, respectively. 
 
 
Overall, compound 83 emerges as the most potent MAO inhibitor of the series, with 
submicromolar potencies against both MAO-A and MAO-B, and hence, essentially 
without selectivity, whereas compounds 33, 36, and 84, with a total number of three 
methylene groups in the tethers that connect their phenyl and triazole rings with the 
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propargylamine nitrogen atom, emerge as low micromolar selective MAO-B inhibitors 
of interest as novel leads for AD drug discovery. 
 
2.3. Reversibility and time-dependent inhibition studies 
The triazole derivative 33, one the most promising compounds of the series by virtue of 
its one-digit micromolar inhibitory potency and MAO-B selectivity, was subjected to 
further studies to gain insight into the type of inhibition of MAO-B. First, we 
investigated whether the propargylamino group present in 33 led to the irreversible 
inhibition of the enzyme. As shown in Figure 4, the reversibility assays confirmed that 
33 irreversibly inhibited MAO-B, since the inhibition was not reverted after various 
cycles of consecutive centrifugations and washings with buffer. Furthermore, this 
finding is in agreement with the time-dependent inhibition of MAO-B resulting from 
incubation with 33, as shown in Figure 4. Thus, after pre-incubation of hrMAO-B with 
a 10 μM concentration of 33 for different times ranging from 5 to 360 min, the 
enzymatic activity showed a slow time-dependent inhibition of MAO-B. These findings 
mimic the behavior reported for the MTDL inhibitor 6,39 and for the structurally related 
MAO-B inhibitor PFN9601.81 As previously noted for 6,39 these results suggest that the 
proper accommodation of 33 in a conformation suitable for covalent attachment to the 
FAD cofactor may require an a priori conformational rearrangement for the structural 
adaptation to the peculiar shape of the MAO-B binding pocket. 
 
 
           
Figure 4. Plot of the enzymatic activity (mFU/min) versus pre-incubation time (min) 
(left) and plot of the remaining enzymatic activity (as % of control sample) versus pre-
incubation time (right) in the study of reversibility of hrMAO-B inhibition by 33.  
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2.4. Blood-brain barrier permeation assay 
Because an essential feature of anti-neurodegenerative drug candidates is the ability to 
cross the BBB, all the novel compounds were subjected to the well-established 
PAMPA-BBB assay, as an in vitro model of passive permeation.82 The in vitro 
permeability (Pe) of the novel compounds through a lipid extract of porcine brain was 
determined using a mixture of phosphate-buffered saline (PBS)/EtOH 70:30. Assay 
validation was carried out by comparison of the experimental and reported permeability 
values of 14 commercial drugs (see Table S1 in Supplementary Material), which 
provided a good linear correlation: Pe (exp) = 1.003 Pe (lit) ‒ 0.783 (R2 = 0.93). Using 
this equation and the limits established by Di et al. for BBB permeation,82 the following 
ranges of permeability were established: Pe (10‒6 cm s‒1) > 5.18 for compounds with 
high BBB permeation (CNS+); Pe (10‒6 cm s‒1) < 2.06 for compounds with low BBB 
permeation (CNS‒); and  5.18 > Pe (10‒6 cm s‒1) > 2.06 for compounds with uncertain 
BBB permeation (CNS±). As shown in Table 1, the tested compounds had generally Pe 
values well above the threshold for high BBB permeation, so that they were predicted to 
be able to cross the BBB and reach their biological target in the CNS, although 
unexpectedly the third generation compounds showed lower permeabilities than the rest 
of compounds, maybe as a consequence of solubility issues 
 
 
3. Conclusion 
The results reported in this study support the feasibility of the CuAAC-mediated 
synthesis of 1,2,3-triazole derivatives featuring the propargylamine group typical of 
irreversible MAO-A and MAO-B inhibitors, leading to suitable templates for the design 
of MAO-B inhibitor-based MTDLs. The synthetic procedures of the 1,4-disubstituted or 
1,4,5-trisubstituted 1,2,3-triazole scaffolds involve 4‒6-step sequences from the 
CuAAC of alkyl or phenyl azides with an alkyne bearing an N-Boc-protected primary 
amino or a cyano group as precursors of the propargylamine warhead. Nevertheless, 
introduction of lipophilic substitutents were necessary to counterbalance the high 
polarity conferred by the triazole ring and to modulate the inhibitory activity against the 
two MAO isoforms. The triazolyl-p-xylyl propargylamine 83 has been found to be a 
moderately potent nonselective MAO inhibitor, with submicromolar potencies against 
both human MAO-A and MAO-B. On the other hand, the isomeric 1-
benzyltriazolylethyl propargylamine 33 and 1-phenethyltriazolylmethyl propargylamine 
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36, and the triazolyl-p-methylphenethyl propargylamine 84 have emerged as moderately 
potent and selective MAO-B inhibitor with low micromolar potencies and large 
selectivity indices, with an appropriate hydrophilic-lipophilic balance (LogP values of 
2.1, 1.9, and 2.4, respectively, i.e. in the range of classical MAO inhibitors) and 
relatively low molecular weight (254‒268). Further work will be focused on refining the 
MAO-B inhibitory potency of these scaffolds by enabling the linkage to a second 
pharmacophoric moiety to derive novel MTDLs, as well as to develop small-molecule 
probes for MAO-B imaging in models of neurodegenerative diseases.83 
 
 
4. Experimental part 
4.1. Chemistry. General methods 
Melting points were determined in open capillary tubes with a MFB 595010M 
Gallenkamp melting point apparatus. 400 MHz 1H/100.6 MHz 13C NMR spectra were 
recorded on a Varian Mercury 400 spectrometer at the Centres Científics i Tecnològics 
of the University of Barcelona (CCiTUB). The chemical shifts are reported in ppm (δ 
scale) relative to solvent signals (CD3OD at 3.31 and 49.0 ppm in the 1H and 13 C NMR 
spectra, respectively; CDCl3 at 7.26 and 77.16 ppm in the 1H and 13 C NMR spectra, 
respectively), and coupling constants are reported in Hertz (Hz). Assignments given for 
the NMR spectra of the new compounds have been carried out by comparison with the 
NMR data of compounds 10, 25, 34, 37, 52, and 82, which in turn, were assigned on the 
basis of DEPT, COSY 1H/1H (standard procedures), and COSY 1H/13C (gHSQC or 
gHMBC sequences) experiments. IR spectra were run on a Perkin-Elmer Spectrum RX 
I spectrophotometer. Absorption values are expressed as wavenumbers (cm1); only 
significant absorption bands are given. Column chromatography was performed on 
silica gel 60 AC.C (4060 mesh, SDS, ref 2000027). Thin-layer chromatography was 
performed with aluminum-backed sheets with silica gel 60 F254 (Merck, ref 1.05554), 
and spots were visualized with UV light and 1% aqueous solution of KMnO4. High 
resolution mass spectra were carried out at the CCiTUB with a LC/MSD TOF Agilent 
Technologies spectrometer. The analytical samples of all of the compounds that were 
subjected to pharmacological evaluation were dried at 65 ºC / 2 Torr (standard 
conditions).  
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4.1.1. N-(tert-Butoxycarbonyl)-N-[(1-ethyl-1H-1,2,3-triazol-4-yl)methyl]amine 9 
To a solution of bromoethane (0.53 mL, 774 mg, 7.10 mmol) in H2O / DMF 1:4 (50 
mL), NaN3 (502 mg, 7.72 mmol), Na2CO3 (2.05 g, 19.3 mmol), ascorbic acid (907 mg, 
5.15 mmol), CuSO4·5H2O (641 mmg, 2.57 mmol) and N-Boc-propargylamine, 7 (1.00 
g, 6.44 mmol) were added. The reaction mixture was stirred at rt overnight, diluted with 
20% aq. NH4OH (200 mL), treated with solid EDTA (ca 5 g) and extracted with EtOAc 
(2 × 150 mL). The combined organic extracts were washed with H2O (3 × 100 mL), 
dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting 
residue was washed with pentane (3 × 10 mL) and dried under vacuum, to give 
compound 9 (1.14 g, 78% yield) as a white solid; Rf 0.57 (CH2Cl2 / MeOH 9:1); mp 
7778 ºC; IR (ATR) ν 3318 (NH), 1685, 1675 (C=O) cm–1; 1H NMR (400 MHz, 
CDCl3) δ 1.40 [s, 9H, C(CH3)3], 1.51 (t, J = 7.2 Hz, 3H, 1CH2CH3), 4.35 (q, J = 7.2 
Hz, 2H, 1CH2CH3), 4.36 (s, 2H, 4CH2NH), 5.21 (broad s, 1H, NHBoc), 7.50 (s, 
1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 15.5 (CH3, 1CH2CH3), 28.4 [3CH3, 
C(CH3)3], 36.2 (CH2, 4CH2N), 45.3 (CH2, 1CH2CH3), 79.7 [C, C(CH3)3], 121.3 
(CH, C5), 145.6 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for (C10H18N4O2 + H+) 
227.1503, found 227.1493. 
 
4.1.2. N-(tert-Butoxycarbonyl)-N-[2-(1-ethyl-1H-1,2,3-triazol-4-yl)ethyl]amine 10 
It was prepared as described for 9. From bromoethane (0.65 mL, 949 mg, 8.71 mmol), 
NaN3 (618 mg, 9.51 mmol), Na2CO3 (2.52 g, 23.8 mmol), ascorbic acid (1.12 g, 6.36 
mmol), CuSO4·5H2O (790 mg, 3.16 mmol), and N-Boc-3-butynylamine, 8 (1.34 g, 7.92 
mmol), compound 10 (1.48 g, 78% yield) was obtained as a white solid; Rf 0.50 
(CH2Cl2 / MeOH 9:1); mp 7880 ºC; IR (ATR) ν 3341 (NH), 1692 (C=O) cm–1; 1H 
NMR (400 MHz, CDCl3) δ 1.40 [s, 9H, C(CH3)3], 1.51 (t, J = 7.6 Hz, 3H, 
1CH2CH3), 2.87 (t, J = 6.4 Hz, 2H, 4CH2CH2NH), 3.44 (dt, J = J’ = 6.4 Hz, 2H, 
4CH2CH2NH), 4.35 (q, J = 7.6 Hz, 2H, 1CH2CH3), 5.04 (broad s, 1H, NHBoc), 
7.35 (s, 1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 15.6 (CH3, 1CH2CH3), 26.3 
(CH2, 4CH2CH2N), 28.5 [3CH3, C(CH3)3], 39.9 (CH2, 4CH2CH2N), 45.2 (CH2, 
1CH2CH3), 79.2 [C, C(CH3)3], 120.8 (CH, C5), 145.5 (C, C4), 156.1 (C, NCOO); 
HRMS (ESI), calcd for (C11H20N4O2 + H+) 241.1659, found 241.1654. 
 
4.1.3. N-(tert-Butoxycarbonyl)-N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethyl]amine 11 
 20 
It was prepared as described for 9. From benzyl bromide (0.75 mL, 1.08 g, 6.31 mmol), 
NaN3 (462 mg, 7.11 mmol), Na2CO3 (1.88 g, 17.7 mmol), ascorbic acid (834 mg, 4.74 
mmol), CuSO4·5H2O (590 mg, 2.36 mmol), and N-Boc-3-butynylamine, 8 (1.00 g, 5.91 
mmol), compound 11 (1.27 g, 71% yield) was obtained as a white solid; Rf 0.58 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 103105 ºC; IR (ATR) v 3407 
(NH), 1688 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.38 [s, 9H, C(CH3)3], 2.84 (t, 
J = 6.8 Hz, 2H, 4CH2CH2NH), 3.41 (td, J = 6.8 Hz, J’ = 6.0 Hz, 2H, 
4CH2CH2NH), 5.04 (broad s, 1H, NHBoc), 5.46 (s, 2H, 1CH2Ph), 7.22 [ddm, J = 
7.6 Hz, J’ = 2.0 Hz, 2H, PhC2(6) H], 7.297.37 [complex signal, 4H, 5-H, 
PhC3(5)H, PhC4H]; 13C NMR (100.6 MHz, CDCl3) δ 26.3 (CH2, 4CH2CH2N), 
28.4 [3CH3, C(CH3)3], 39.8 (CH2, 4CH2CH2N), 54.1 (CH2, 1CH2Ph), 79.2 [C, 
C(CH3)3], 121.4 (CH, C5), 128.1 (2CH), 128.8 (CH), 129.2 (2CH) (PhCH), 134.8 (C, 
PhC1), 145.9 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for (C16H22N4O2 + H+) 
303.1816, found 303.1813. 
 
4.1.4. N-(tert-Butoxycarbonyl)-N-[2-(1-phenethyl-1H-1,2,3-triazol-4-yl)ethyl]amine 12 
It was prepared as described for 9. From phenethyl bromide (0.89 mL, 1.21 g, 6.52 
mmol), NaN3 (462 mg, 7.11 mmol), Na2CO3 (1.88 g, 17.7 mmol), ascorbic acid (834 
mg, 4.74 mmol), CuSO4·5H2O (590 mg, 2.36 mmol), and N-Boc-3-butynylamine, 8 
(1.00 g, 5.91 mmol), compound 12 (908 mg, 49% yield) was obtained as a white solid; 
Rf 0.52 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 123125 ºC; IR (ATR) v 
3392 (NH), 1688 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.43 [s, 9H, C(CH3)3], 
2.85 (t, J = 6.8 Hz, 2H, 4CH2CH2N), 3.19 (t, J = 7.2 Hz 2H, 1CH2CH2Ph), 3.42 
(m, 2H, 4CH2CH2N), 4.55 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.95 (br s, 1H, 
NHBoc), 7.09 [dm, J = 6.8 Hz, 2H, PhC2(6) H], 7.227.32 [complex signal, 4H, 5-
H, PhC3(5)H, PhC4H]; 13C NMR (100.6 MHz, CDCl3) δ 26.2 (CH2, 
4CH2CH2N), 28.5 [3CH3, C(CH3)3], 36.9 (CH2, 1CH2CH2Ph), 40.0 (CH2, 
4CH2CH2N), 51.6 (CH2, 1CH2CH2Ph), 79.3 [C, C(CH3)3], 121.9 (CH, C5), 
127.2 (CH), 128.8 (2CH), 128.9 (2CH) (PhCH), 137.2 (C, PhC1), 145.2 (C, C4), 
156.1 (C, NCOO); HRMS (ESI), calcd for (C17H24N4O2 + H+) 317.1972, found 
317.1968. 
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4.1.5. N-(tert-Butoxycarbonyl)-N-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]amine 13 
It was prepared as described for 9. From iodomethane (0.44 mL, 1.00 g, 7.07 mmol), 
NaN3 (502 mg, 7.72 mmol), Na2CO3 (2.05 g, 19.3 mmol), ascorbic acid (907 mg, 5.15 
mmol), CuSO4·5H2O (641 mg, 2.57 mmol), and N-Boc-propargylamine, 7 (1.00 g, 6.44 
mmol), compound 13 (938 mg, 69% yield) was obtained as a white solid; Rf 0.87 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 102‒104 ºC; IR (ATR) v 3379 
(NH), 1679 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.41 [s, 9H, C(CH3)3], 4.05 (s, 
3H, 1CH3), 4.35 (d, J = 6.0 Hz, 2H, 4CH2N), 5.17 (br s, 1H, NHBoc), 7.48 (s, 1H, 
5-H); 13C NMR (100.6 MHz, CDCl3) δ: 28.5 [3CH3, C(CH3)3], 36.2 (CH2, 4CH2N), 
36.7 (CH3, 1CH3), 79.7 [C, C(CH3)3], 122.9 (CH, C5), 145.9 (C, C4), 156.0 (C, 
NCOO); HRMS (ESI), calcd for (C9H16N4O2 + H+) 213.1346, found 213.1336. 
 
4.1.6. N-(tert-Butoxycarbonyl)-N-[2-(1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]amine 14 
It was prepared as described for 9. From phenyl azide (0.5 M solution in tert-butyl 
methyl ether, 26.2 mL, 13.1 mmol), Na2CO3 (3.47 g, 32.7 mmol), ascorbic acid (1.54 g, 
8.74 mmol), CuSO4·5H2O (1.09 mmg, 4.36 mmol), and N-Boc-3-butynylamine, 8 (2.00 
g, 11.8 mmol), compound 14 (1.89 g, 56% yield) was obtained as a yellow solid; Rf 0.90 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05); mp 127129 ºC; IR (ATR) v 3297 
(NH), 1712 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.43 [s, 9H, C(CH3)3], 3.00 (t, 
J = 6.8 Hz, 2H, 4CH2CH2N), 3.55 (td, J = 6.8 Hz, J’ = 6.0 Hz, 2H, 
4CH2CH2N), 5.02 (br s, 1H, NHBoc), 7.43 (tt, J = 7.4 Hz, J’ = 1.2 Hz, 1H, 
PhC4H), 7.52 [m, 2H, PhC3(5)-H], 7.71 [ddd, J = 8.8 Hz, J’ = 2.4 Hz, J” = 1.2 Hz, 
2H, PhC2(6)H], 7.81 (s, 1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 26.4 (CH2, 
4CH2CH2N), 28.5 [3CH3, C(CH3)3], 39.9 (CH2, 4CH2CH2N), 79.4 [C, 
C(CH3)3], 119.8 (CH, PhC4), 120.5 (CH, C5), 128.7 (2CH), 129.9 (2CH) [PhC2(6), 
PhC3(5)], 137.2 (C, PhC1), 146.3 (C, C4), 156.1 (C, NCOO); HRMS (ESI), calcd for 
(C15H20N4O2 + Na+) 311.1478, found 311.1476. 
 
4.1.7. N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-(tert-butoxycarbonyl)amine 15 
It was prepared as described for 9. From benzyl bromide (1.04 mL, 1.50 g, 8.74 mmol), 
NaN3 (622 mg, 9.57 mmol), Na2CO3 (2.53 g, 23.9 mmol), ascorbic acid (1.12 g, 6.36 
mmol), CuSO4·5H2O (796 mg, 3.19 mmol), and N-Boc-propargylamine, 7 (1.24 g, 7.99 
mmol), compound 15 (1.68 g, 68% yield) was obtained as a white solid; Rf 0.62 
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(CH2Cl2 / MeOH / NH4OH 9.75:0.25:0.05); mp 9799 ºC; IR (ATR) v 3400, 3302, 
3105, 3059 (NH), 1684, 1679 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.32 [s, 9H, 
C(CH3)3], 4.27 (d, J = 6.0 Hz, 2H, 4CH2N), 5.06 (br s, 1H, NHBoc), 5.40 (s, 2H, 
1CH2Ph), 7.26 [m, 2H, PhC2(6)H], 7.307.40 [complex signal, 3H, PhC3(5)H, 
PhC4H], 7.43 (s, 1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 28.4 [3CH3, C(CH3)3], 
36.2 (CH2, 4CH2N), 54.2 (CH2, 1CH2Ph), 79.8 [C, C(CH3)3], 121.9 (CH, C5), 
128.2 (2CH), 128.8 (CH), 129.2 (2CH) (PhCH), 134.7 (C, PhC1), 146.0 (C, C4), 
155.9 (C, NCOO); HRMS (ESI), calcd for (C15H20N4O2 + Na+) 311.1478, found 
311.1487. 
 
4.1.8. N-(tert-Butoxycarbonyl)-N-[(1-phenethyl-1H-1,2,3-triazol-4-yl)methyl]amine 16 
It was prepared as described for 9. From phenethyl bromide (1.11 mL, 1.50 g, 8.13 
mmol), NaN3 (574 mg, 8.83 mmol), Na2CO3 (2.34 g, 22.1 mmol), ascorbic acid (1.04 g, 
5.91 mmol), CuSO4·5H2O (735 mg, 2.94 mmol), and N-Boc-propargylamine, 7 (1.00 g, 
6.44 mmol), compound 16 (1.43 g, 73% yield) was obtained as a white solid; Rf 0.57 
(CH2Cl2 / MeOH / NH4OH 9.75:0.25:0.05); mp 98100 ºC; IR (ATR) v 3410, 3111, 
3069, 3054 (NH), 1684 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.43 [s, 9H, 
C(CH3)3], 3.19 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.34 (d, J = 6.0 Hz, 2H, 
4CH2N), 4.56 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 5.14 (br s, 1H, NHBoc), 7.10 
[dm, J = 8.4 Hz, 2H, PhC2(6)H], 7.217.32 [complex signal, 4H, 5-H, PhC3(5)H, 
PhC4H]; 13C NMR (100.6 MHz, CDCl3) δ 28.5 [3CH3, C(CH3)3], 36.2 (CH2, 
4CH2N), 36.8 (CH2, 1CH2CH2Ph), 51.7 (CH2, 1CH2CH2Ph), 79.7 [C, 
C(CH3)3], 122.2 (CH, C5), 127.2 (CH), 128.7 (2CH), 128.9 (2CH) (PhCH), 137.0 (C, 
PhC1), 145.3 (C, C4), 155.9 (C, NCOO); HRMS (ESI), calcd for (C16H22N4O2 + H+) 
303.1816, found 303.1827. 
 
4.1.9. N-(tert-Butoxycarbonyl)-N-[(1-ethyl-1H-1,2,3-triazol-4-yl)methyl]-N-
methylamine 17 
A solution of 9 (634 mg, 2.80 mmol) in anhydrous THF (6.5 mL) was cooled to 0 ºC 
and treated with NaH (60% suspension in mineral oil, 246 mg, 6.15 mmol) and 
iodomethane (0.19 mL, 433 mg, 3.05 mmol). The reaction mixture was stirred at rt for 3 
h, cooled to 0 ºC, diluted dropwise with sat. aq. NH4Cl (40 mL), and extracted with 
EtOAc (3 × 40 mL). The combined organic extracts were dried over anhydrous Na2SO4 
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and evaporated under reduced pressure. The resulting residue was washed with pentane 
(3 × 10 mL) and dried under vacuum, to give 17 (654 mg, 97% yield) as a colorless oil; 
Rf 0.64 (CH2Cl2 / MeOH 9:1); IR (ATR) ν 1688, 1677 (C=O) cm–1; 1H NMR (400 
MHz, CDCl3) δ 1.40 [s, C(CH3)3 minor rotamer], 1.42 [s, C(CH3)3 major rotamer], 1.50 
(t, J = 7.2 Hz, 1‒CH2‒CH3 minor rotamer), 1.51 (t, J = 7.2 Hz, 1‒CH2‒CH3 major 
rotamer), 2.87 (s, 3H, NCH3), 4.39 (q, J = 7.2 Hz, 1‒CH2‒CH3 minor rotamer), 4.40 
(q, J = 7.2 Hz, 1‒CH2‒CH3 major rotamer), 4.49 (s, 4‒CH2‒N), 7.37 (br s, 5-H minor 
rotamer), 7.49 (s, 5-H major rotamer); HRMS (ESI), calcd for (C11H20N4O2 + H+) 
241.1659, found 241.1654. 
 
4.1.10. N-(tert-Butoxycarbonyl)-N-[2-(1-ethyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
methylamine 18 
It was prepared as described for 17. From compound 10 (1.70 g, 7.08 mmol), NaH 
(60% supension in mineral oil, 424 mg, 10.6 mmol), and iodomethane (0.48 mL, 1.09 g, 
7.71 mmol), stirring at rt for 2 h, compound 18 (1.71 mg, 95% yield) was obtained as a 
colorless oil; Rf 0.58 (CH2Cl2 / MeOH 9:1); IR (ATR) ν 1690 (C=O) cm–1; 1H NMR 
(400 MHz, CDCl3) δ 1.41 [s, 9H, C(CH3)3], 1.51 (t, J = 7.2 Hz, 3H, 1CH2CH3), 2.82 
(s, 3H, NCH3), 2.93 (m, 2H, 4CH2CH2N), 3.52 (br t, J = 6.8 Hz, 2H, 
4CH2CH2N), 4.35 (q, J = 7.2 Hz, 2H, 1CH2CH3), 7.28 (br s), 7.40 (br s) (5-H); 
13C NMR (100.6 MHz, CDCl3) δ 15.6 (CH3, 1CH2CH3), 24.3 (CH2), 24.7 (CH2) 
(4CH2CH2N), 28.5 [3CH3, C(CH3)3], 34.4 (CH3, NCH3), 45.2 (CH2, 1CH2CH3), 
48.0 (CH2), 48.9 (CH2) (4CH2CH2N), 79.5 [C, C(CH3)3], 120.8 (CH, C5), 145.2 (br 
C, C4), 155.8 (br C, NCOO); HRMS (ESI), calcd for (C12H22N4O2 + H+) 255.1816, 
found 255.1815. 
 
4.1.11. N-(tert-Butoxycarbonyl)-N-[2-(1-benzyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
methylamine 19 
It was prepared as described for 17. From compound 11 (3.67 g, 12.1 mmol), NaH 
(60% supension in mineral oil, 0.73 g, 18.2 mmol), and iodomethane (0.83 mL, 1.89 g, 
13.3 mmol), stirring at rt for 3 h, compound 19 (3.64 g, 95% yield) was obtained as a 
yellowish oil; Rf 0.60 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); IR (ATR) v 
1687 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.37 [s, 9H, C(CH3)3], 2.78 (s, 3H, 
NCH3), 2.90 (m, 2H, 4CH2CH2N), 3.48 (t, J = 6.8 Hz, 2H, 4CH2CH2N), 5.45 
 24 
(s, 2H, 1CH2-Ph), 7.207.37 (complex signal, 6H, 5-H, PhCH); 13C NMR (100.6 
MHz, CDCl3) δ 24.2 (CH2), 24.7 (CH2) (4CH2CH2N), 28.4 [3CH3, C(CH3)3], 34.4 
[CH3, NCH3), 48.0 (CH2), 48.7 (CH2) (4CH2CH2N), 54.1 (CH2, 1CH2Ph), 79.5 
[C, C(CH3)3], 121.4 (br CH, C5), 128.1 (2CH), 128.7 (CH), 129.1 (2CH) (PhCH), 
134.9 (C, PhC1), 145.6 (br C, C4), 155.7 (C, NCOO); HRMS (ESI), calcd for 
(C17H24N4O2 + H+) 317.1972, found 317.1964. 
 
4.1.12. N-(tert-Butoxycarbonyl)-N-methyl-N-[2-(1-phenethyl-1H-1,2,3-triazol-4-
yl)ethyl]amine 20 
It was prepared as described for 17. From compound 12 (876 mg, 2.77 mmol), NaH 
(60% supension in mineral oil, 167 mg, 4.17 mmol), and iodomethane (0.19 mL, 433 
mg, 3.05 mmol), stirring at rt for 1.5 h, compound 20 (738 mg, 81% yield) was obtained 
as a yellowish oil; Rf 0.57 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 5860 
ºC; IR (ATR) v 1686 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.42 [s, 9H, C(CH3)3], 
2.80 (s, 3H, NCH3), 2.90 (m, 2H, 4CH2CH2N), 3.18 (t, J = 7.2 Hz, 2H, 
1CH2CH2Ph), 3.48 (m, 2H, 4CH2CH2N), 4.54 (t, J = 7.2 Hz, 2H, 
1CH2CH2Ph), 7.03 (br s), 7.19 (br s) (5-H), 7.10 [dm, J = 8.0 Hz, 2H, 
PhC2(6)H], 7.217.32 (complex signal, 3H, PhC3(5)H, PhC4H]; 13C NMR 
(100.6 MHz, CDCl3) δ 24.2 (CH2), 24.6 (CH2) (4CH2CH2N), 28.5 (3CH3, C(CH3)3], 
34.5 (CH3, NCH3), 36.9 (CH2, 1CH2CH2Ph), 48.1 (CH2), 48.9 (CH2) 
(4CH2CH2N), 51.6 (CH2, 1CH2CH2Ph), 79.5 [C, C(CH3)3], 121.8 (CH, C5), 
127.1 (CH), 128.7 (2CH), 128.9 (2CH) (PhCH), 137.2 (C, PhC1), 144.8 (br C, C4), 
155.8 (C, NCOO); HRMS (ESI), calcd for (C18H26N4O2 + H+) 331.2129, found 
331.2122. 
 
4.1.13. N-(tert-Butoxycarbonyl)-N-methyl-N-[(1-methyl-1H-1,2,3-triazol-4-
yl)methyl]amine 21 
It was prepared as described for 17. From compound 13 (928 mg, 4.38 mmol), NaH 
(60% supension in mineral oil, 263 mg, 6.57 mmol), and iodomethane (0.30 mL, 684 
mg, 4.82 mmol), stirring at rt for 1.5 h, compound 21 (945 mg, 95% yield) was obtained 
as a yellowish oil; Rf 0.31 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); IR  (ATR) 
v 1686 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.45 [s, 9H, C(CH3)3], 2.89 (s, 3H, 
NCH3), 4.07 (s, 3H, 1CH3), 4.47 (s, 2H, 4CH2N), 7.37 (br s), 7.49 (broad s) (5-H); 
 25 
13C NMR (100.6 MHz, CDCl3) δ 28.6 [3CH3, C(CH3)3], 34.2 (br CH3), 34.6 (br CH3) 
(NCH3), 36.8 (CH3, 1CH3), 43.8 (br CH2), 44.5 (br CH2) (4CH2N), 79.9 [br C, 
C(CH3)3], 122.6 (br CH), 123.5 (br CH) (C5), 145.3 (br C), 145.8 (br C) (C4), 155.3 (br 
C), 155.9 (br C) (NCOO); HRMS (ESI), calcd for (C10H18N4O2 + Na+) 249.1322; found 
249.1323. 
 
4.1.14. N-(tert-Butoxycarbonyl)-N-methyl-N-[2-(1-phenyl-1H-1,2,3-triazol-4-
yl)ethyl]amine 22 
It was prepared as described for 17. From compound 14 (1.82 g, 6.32 mmol), NaH 
(60% supension in mineral oil, 0.76 g, 19.0 mmol), and iodomethane (1.96 mL, 4.47 g, 
31.5 mmol), stirring at rt overnight, compound 22 (1.82 g, 95% yield) was obtained as a 
yellowish oil; Rf 0.86 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05); IR (ATR) v 1689, 
1681 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.42 [s, 9H, C(CH3)3], 2.88 (s, 3H, 
NCH3), 3.04 (m, 2H, 4CH2CH2N), 3.61 (m, 2H, 4CH2CH2N), 7.43 (m, 1H, 
PhC4H), 7.51 [m, 2H, PhC3(5)H], 7.71 [dm, J = 8.8 Hz, 2H, PhC2(6)H], 7.89 
(br s, 1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 24.3 (br CH2), 24.6 (br CH2) 
(4CH2CH2N), 28.5 [3CH3, C(CH3)3], 34.4 (CH3, NCH3), 47.8 (br CH2), 48.7 (br 
CH2) (4CH2CH2N), 79.6 [C, C(CH3)3], 119.8 (CH, PhC4), 120.5 (CH, C5), 128.6 
(2CH), 129.8 (2CH) [PhC2(6), PhC3(5)], 137.2 (C, PhC1), 145.9 (br C, C4), 155.8 
(br C, NCOO); HRMS (ESI), calcd for (C16H22N4O2 + H+) 303.1816, found 303.1809. 
 
4.1.15. N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-(tert-butoxycarbonyl)-N-
methylamine 23 
It was prepared as described for 17. From compound 15 (1.60 g, 5.16 mmol), NaH 
(60% suspension in mineral oil, 670 mg, 16.7 mmol), and iodomethane (1.73 mL, 3.94 
g, 27.8 mmol), stirring at rt overnight, compound 23 (1.30 g, 83% yield) was obtained 
as a brown solid; Rf 0.68 (CH2Cl2 / MeOH / NH4OH 9.75:0.25:0.05); mp 7981 ºC; IR 
(ATR) v 1679 (C=O) cm-1; 1H NMR (400 MHz, CDCl3) δ 1.41 [br s, 9H, C(CH3)3], 
2.89 (s, 3H, NCH3), 4.45 (s, 2H, 4CH2N), 5.50 (s, 2H, 1CH2Ph), 7.26 [br dd, J = 
8.0 Hz, J’ = 1.6 Hz, 2H, PhC2(6)H], 7.347.40 [complex signal, 3H, PhC3(5)H, 
PhC4H], 7.44 (br s, 1H, 5-H); 13C NMR (100.6 MHz, CDCl3) δ 28.4 [3CH3, 
C(CH3)3], 34.5 (CH3, NCH3), 43.8 (CH2), 44.6 (CH2) (4CH2N), 54.2 (CH2, 
1CH2Ph), 79.8 [C, C(CH3)3], 121.6 (CH), 122.4 (CH) (C5), 128.1 (2CH), 128.8 
 26 
(CH), 129.2 (2CH) (PhCH), 134.7 (C, PhC1), 145.4 (C), 145.6 (C) (C4), 155.4 (C), 
155.8 (C) (NCOO); HRMS (ESI), calcd for (C16H22N4O2 + Na+) 325.1635, found 
325.1638. 
 
4.1.16. N-(tert-Butoxycarbonyl)-N-methyl-N-[(1-phenetyl-1H-1,2,3-triazol-4-
yl)methyl]amine 24 
It was prepared as described for 17. From compound 16 (1.27 g, 4.20 mmol), NaH 
(60% suspension in mineral oil, 505 mg, 12.6 mmol), and iodomethane (1.31 mL, 2.99 
g, 21.0 mmol), stirring at rt overnight, compound 24 (1.07 g, 81% yield) was obtained 
as a brown oil; Rf 0.59 (CH2Cl2 / MeOH / NH4OH 9.75:0.25:0.05); IR (ATR) v 1687 
(C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.43 [s, 9H, C(CH3)3], 2.84 (s, 3H, 
NCH3), 3.19 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.43 (s, 2H, 4CH2N), 4.56 (m, 
2H, 1CH2CH2Ph), 7.08 [dm, J = 8.4 Hz, 2H, PhC2(6)H], 7.207.32 [complex 
signal, 4H, 5-H, PhC3(5)H, PhC4H]; 13C NMR (100.6 MHz, CDCl3) δ 28.2 [CH3, 
C(CH3)3 minor rotamer], 28.3 [CH3, C(CH3)3 major rotamer], 33.9 (CH3, NCH3 minor 
rotamer), 34.2 (CH3, NCH3 major rotamer), 36.5 (CH2, 1CH2CH2Ph minor 
rotamer), 36.6 (CH2, 1CH2CH2Ph major rotamer), 43.5 (CH2, 4CH2N major 
rotamer), 44.2 (CH2, 4CH2N minor rotamer), 51.4 (CH2, 1CH2CH2Ph minor 
rotamer), 51.5 (CH2, 1CH2CH2Ph major rotamer), 79.6 [br C, C(CH3)3], 121.9 (CH, 
C5 minor rotamer), 122.6 (CH, C5 major rotamer),  126.8 (CH, PhC4 minor rotamer), 
127.0 (CH, PhC4 major rotamer), 128.4 (CH), 128.5 (CH), 128.7 (CH) [PhC2(6), 
PhC3(5)], 136.8 (C, PhC1 minor rotamer), 136.9 (C, PhC1 major rotamer), 144.4 
(br C, C4), 155.2 (C, NCOO minor rotamer), 155.7 (C, NCOO major rotamer); HRMS 
(ESI), calcd for (C17H24N4O2 + H+) 317.1972, found 317.1979. 
 
4.1.17. N-[(1-Ethyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 25 
To a solution of 17 (411 mg, 1.71 mmol) in CH2Cl2 (6 mL), H3PO4 (85% purity, 2.96 
mL, 25.7 mmol) was added. The reaction mixture was stirred at rt for 2 h, cooled to 0 
ºC, diluted with H2O (15 mL), alkalinized dropwise to pH = 14 with 5 N NaOH, and 
extracted with CH2Cl2 (2 × 30 mL). The combined organic extracts were dried over 
anhydrous Na2SO4 and evaporated under reduced pressure to give amine 25 (205 mg, 
86% yield) as a colorless oil; Rf 0.07 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
 27 
A solution of amine 25 (25 mg, 0.18 mmol) in CH2Cl2 (4 mL) was filtered through a 
PTFE filter (0.2 µm), treated with a HCl / MeOH solution (0.75 N, 0.71 mL, 0.53 
mmol), and evaporated under reduced pressure. The resulting residue was washed with 
pentane (3 × 2 mL) to give, after drying under standard conditions, 25·HCl (28 mg) as a 
beige sticky solid; IR (ATR) ν 35002500 (max at 3386, 3126, 3080, 3028, 2981, 2935, 
2756, 2695, +NH and CH) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.55 (t, J = 7.2 Hz, 
3H, 1CH2CH3), 2.76 (s, 3H, NCH3), 4.35 (s, 2H, 4CH2N), 4.50 (q, J = 7.2 Hz, 
2H, 1CH2CH3), 4.96 (s, +NH2), 8.22 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 
15.8 (CH3, 1CH2CH3), 33.1 (CH3, NCH3), 44.2 (CH2, 4CH2N), 46.8 (CH2, 
1CH2CH3), 126.2 (CH, C5), 139.3 (C, C4); HRMS (ESI), calcd for (C6H12N4 + H+) 
141.1135, found 141.1133. 
 
4.1.18. N-[2-(1-Ethyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 26 
It was prepared as described for 25. From 18 (263 mg, 1.03 mmol) and H3PO4 (85% 
purity, 1.80 mL, 15.6 mmol), and stirring at rt for 4 h, amine 26 (143 mg, 90% yield) 
was obtained as a colorless oil; Rf 0.07  (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
26·HCl: beige sticky solid, IR (ATR) ν 35002400 (max at 3395, 3116, 3064, 2976, 
2936, 2752, 2691, 2446, +NH and CH) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.54 (t, 
J = 7.2 Hz, 3H, 1CH2CH3), 2.76 (s, 3H, NCH3), 3.17 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 3.37 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.48 (q, J = 7.2 Hz, 2H, 
1CH2CH3), 4.87 (s, +NH2), 8.07 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 15.6 
(CH3, 1CH2CH3), 22.9 (CH2, 4CH2CH2N), 33.7 (CH3, NCH3), 47.1 (CH2, 
1CH2CH3), 49.3 (CH2, 4CH2CH2N), 124.6 (CH, C5), 143.3 (C, C4); HRMS 
(ESI), calcd for (C7H14N4 + H+) 155.1291, found 155.1297. 
 
4.1.19. N-[2-(1-Benzyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 27 
It was prepared as described for 25. From 19 (1.12 g, 3.54 mmol) and H3PO4 (85% 
purity, 6.08 mL, 52.7 mmol), amine 27 (721 mg, 94% yield) was obtained as a yellow 
oil; Rf 0.23 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
27·HCl: beige solid, mp 189190 ºC; IR (ATR) v 36002400 (max at 3554, 3064, 3013, 
2927, 2868, 2735, 2685, 2447, C-H, +NH and CH) cm–1; 1H NMR (400 MHz, 
CD3OD) δ 2.75 (s, 3H, NCH3), 3.24 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 3.38 (t, J = 
7.2 Hz, 2H, 4CH2CH2N), 4.98 (s, +NH2), 5.72 (s, 2H, 1CH2Ph), 7.357.46 
 28 
(complex signal, 5H, PhCH), 8.30 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 
22.4 (CH2, 4CH2CH2N), 33.7 (CH3, NCH3), 48.6 (CH2, 4CH2CH2N), 56.5 
(CH2, 1-CH2-Ph), 126.6 (CH, C5), 129.8 (2CH), 130.15 (CH), 130.20 (2CH) (PhCH), 
135.3 (C, PhC1), 142.6 (C, C4); HRMS (ESI), calcd for (C12H16N4 + H+) 217.1448, 
found 217.1442. 
 
4.1.20. N-Methyl-N-[2-(1-phenethyl-1H-1,2,3-triazol-4-yl)ethyl]amine 28 
It was prepared as described for 25. From 20 (693 mg, 2.10 mmol) and H3PO4 (85% 
purity, 3.61 mL, 31.3 mmol), amine 28 (472 mg, 98% yield) was obtained as a yellow 
oil; Rf 0.26 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
28·HCl: beige solid, mp 160162 ºC; IR (ATR) v 35002400 (max at 3413, 3354, 3126, 
3092, 2954, 2783, 2703, 2444, +NH and CH) cm–1; 1H NMR (400 MHz, CD3OD) δ 
2.75 (s, 3H, NCH3), 3.25 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), overimposed in part 
3.29 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 3.37 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.80 
(t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.99 (s, +NH2), 7.187.30 (complex signal, 5H, 
PhCH), 8.30 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 22.1 (CH2, 
4CH2CH2N), 33.8 (CH3, NCH3), 36.7 (CH2, 1CH2CH2Ph), 48.4 (CH2, 
4CH2CH2N), 54.6 (CH2, 1CH2CH2Ph), 127.5 (CH, C5), 128.2 (CH), 129.8 
(4CH) (PhCH), 137.9 (C, PhC1), 141.6 (C, C4); HRMS (ESI), calcd for (C13H18N4 + 
H+) 231.1604; found 231.1604. 
 
4.1.21. N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 29 
It was prepared as described for 25. From 23 (723 mg, 2.39 mmol) and H3PO4 (85% 
purity, 4.14 mL, 35.9 mmol), amine 29 (420 mg, 87% yield) was obtained as a brown 
oil; Rf 0.14 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.75:0.25:0.05). 
29·HCl: yellow solid, mp 218219 ºC; IR (ATR) v 35002400 (max at 3126, 3059, 
3018, 2981, 2940, 2852, 2770, 2697, +NH and CH) cm–1; 1H NMR (400 MHz, 
CD3OD) δ 2.74 (s, 3H, NCH3), 4.33 (s, 2H, 4CH2N), 4.87 (s, +NH2), 5.64 (s, 2H, 
1‒CH2Ph), 7.317.40 (complex signal, 5H, PhCH), 8.19 (s, 1H, 5-H); 13C NMR 
(100.6 MHz, CD3OD) δ 33.1 (CH3, NCH3), 44.2 (CH2, 4CH2N), 55.0 (CH2, 
1CH2Ph), 126.5 (CH, C5), 129.3 (2CH), 129.7 (CH), 130.0 (2CH) (PhCH), 136.6 
 29 
(C, PhC1), 139.8 (C, C4); HRMS (ESI), calcd for (C11H14N4 + H+) 203.1291, found 
203.1284. 
 
4.1.22. N-Methyl-N-[(1-phenethyl-1H-1,2,3-triazol-4-yl)methyl]amine 30 
It was prepared as described for 25. From 24 (983 mg, 3.11 mmol) and H3PO4 (85% 
purity, 5.37 mL, 46.6 mmol), amine 30 (258 mg, 38% yield) was obtained as a colorless 
oil; Rf 0.16 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.75:0.25:0.05). 
30·HCl: yellow solid, mp 173175 ºC; IR (ATR) v 35002400 (max at 3111, 3069, 
3023, 2981, 2925, 2764, 2749, 2692, 2599, 2542, +NH and CH) cm–1; 1H NMR (400 
MHz, CD3OD) δ 2.67 (s, 3H, NCH3), 3.24 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.26 (s, 
2H, 4CH2N), 4.71 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.87 (s, +NH2), 7.15 [dm, J = 
8.4 Hz, 2H, PhC2(6)H], 7.167.29 [complex signal, 3H, PhC3(5) H, PhC4H], 
7.94 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 32.9 (CH3, NCH3), 37.3 (CH2, 
1CH2CH2Ph), 44.1 (CH2, 4CH2N), 52.7 (CH2, 1CH2CH2Ph), 126.8 (CH, 
C5), 128.0 (CH), 129.7 (2CH), 129.8 (2CH) (PhCH), 138.6 (C, PhC1), 139.0 (C, 
C4); HRMS (ESI), calcd for (C12H16N4 + H+) 217.1448, found 217.1443. 
 
4.1.23. N-[(1-Ethyl-1H-1,2,3-triazol-4-yl)methyl]-N-methyl-N-propargylamine 31 
A solution of amine 25 (85 mg, 0.61 mmol) in anhydrous acetone (20 mL) was cooled 
to 0 ºC and treated with Cs2CO3 (199 mg, 0.61 mmol) and propargyl bromide (80% 
solution in toluene, 0.09 mL, 0.61 mmol). The reaction mixture was stirred at rt 
overnight, then filtered, and evaporated under reduced pressure to give an oily residue 
(161 mg), which was purified through column chromatography (4060 µm silica gel, 
CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / 
MeOH / 50% aq. NH4OH 98:2:0.2, propargylamine 31 (97 mg, 89% yield) was isolated 
as a colorless oil; Rf 0.33 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
31·HCl: beige sticky solid, IR (ATR) ν 35002300 (max at 3412, 3205, 3126, 2987, 
2941, 2568, 2477, 2381, +NH, {CH,  and CH), 2125 (C{C) cm–1; 1H NMR (400 
MHz, CD3OD) δ 1.56 (t, J = 7.6 Hz, 3H, 1CH2CH3), 2.94 (s, 3H, NCH3), 3.39 (t, J 
= 2.4 Hz, 1H, propargyl CH), 4.12 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.50 (q, J = 7.6 
Hz, 2H, 1CH2CH3), 4.54  (s, 2H, 4CH2N), 4.87 (s, +NH), 8.26 (s, 1H, 5-H); 13C 
NMR (100.6 MHz, CD3OD) δ 15.7 (CH3, 1CH2CH3), 40.3 (CH3, NCH3), 45.6 
(CH2, propargyl CH2), 46.8 (CH2, 1CH2CH3), 50.4 (CH2, 4CH2N), 73.3 (C, 
 30 
propargyl C), 81.2 (CH, propargyl CH), 127.4 (CH, C5), 137.8 (C, C4); HRMS (ESI), 
calcd for (C9H14N4 + H+) 179.1291, found 179.1289. 
 
4.1.24. N-[2-(1-Ethyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methyl-N-propargylamine 32 
It was prepared as described for 31. From amine 26 (299 mg, 1.94 mmol), Cs2CO3 (630 
mg, 1.93 mmol), and propargyl bromide (80% solution in toluene, 0.29 mL, 1.95 
mmol), and stirring at 0 ºC for 2.5 h, propargylamine 32 (220 mg, 59% yield) was 
obtained as a yellow oil, without the need of chromatographic purification; Rf 0.55 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
32·HCl: yellow sticky solid, IR (ATR) ν 35002300 (max at 3417, 3191, 2937, 2521, 
2434, 2359, +NH, {CH, and CH), 2121 (C{C) cm–1; 1H NMR (400 MHz, CD3OD) δ 
1.53 (t, J = 7.2 Hz, 3H, 1CH2CH3), 3.05 (s, 3H, NCH3), 3.24 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 3.41 (t, J = 2.8 Hz, 1H, propargyl CH), 3.62 (br t, J = 7.2 Hz, 2H, 
4CH2CH2N), 4.24 (d, J = 2.8 Hz, 2H, propargyl CH2), 4.46 (q, J = 7.2 Hz, 2H, 
1CH2CH3), 4.86 (s, +NH), 8.01 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 15.7 
(CH3, 1CH2CH3), 21.6 (CH2, 4CH2CH2N), 40.7 (CH3, NCH3), 46.3 (CH2, 
propargyl CH2), 46.8 (CH2, 1CH2CH3), 55.4 (CH2, 4CH2CH2N), 72.6 (C, 
propargyl C), 81.6 (CH, propargyl CH), 124.2 (CH, C5), 143.1 (C, C4); HRMS (ESI), 
calcd for (C10H16N4 + H+) 193.1448, found 193.1440. 
 
4.1.25. N-[2-(1-Benzyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methyl-N-propargylamine 33 
It was prepared as described for 31. From amine 27 (690 mg, 3.19 mmol), Cs2CO3 (1.04 
g, 3.19 mmol), and propargyl bromide (80% solution in toluene, 0.47 mL, 3.16 mmol), 
and stirring at rt for 2 h, propargylamine 33 (577 mg, 71 % yield) was obtained as a 
yellow oil, without the need of chromatographic purification; Rf 0.48 (CH2Cl2 / MeOH / 
50% aq. NH4OH 9.5:0.5:0.05). 
33·HCl: brown solid, mp 9799 ºC; IR  (ATR) v 35002300 (max at 3413, 3194, 2948, 
2522, +NH, {CH, and CH), 2124 (C{C) cm1; 1H NMR (400 MHz, CD3OD) δ 3.03 
(s, 3H, NCH3), 3.31 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 3.39 (t, J = 2.4 Hz, 1H, 
propargyl CH), 3.62 (m, 2H, 4CH2CH2N), 4.23 (d, J = 2.4 Hz, 2H, propargyl CH2), 
5.00 (s, +NH), 5.68 (s, 2H, 1CH2Ph), 7.337.43 (complex signal, 5H, PhCH), 8.23 
(s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 21.2 (CH2, 4CH2CH2N), 40.7 (CH3, 
NCH3), 46.4 (CH2, propargyl CH2), 54.8 (CH2, 4CH2CH2N), 56.1 (CH2, 
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1CH2Ph), 72.6 (C, propargyl C), 81.7 (CH, propargyl CH), 126.1 (CH, C5), 129.6 
(2CH), 130.0 (CH), 130.1 (2CH)  (PhCH), 135.6 (C, PhC1), 142.6 (C, C4); HRMS 
(ESI), calcd for (C15H18N4 + H+) 255.1604, found 255.1607. 
 
4.1.26. N-Methyl-N-[2-(1-phenethyl-1H-1,2,3-triazol-4-yl)ethyl]-N-propargylamine 34 
It was prepared as described for 31. From amine 28 (384 mg, 1.67 mmol), Cs2CO3 (543 
mg, 1.67 mmol), and propargyl bromide (80% solution in toluene, 0.25 mL, 1.68 
mmol), and stirring at rt for 2 h, propargylamine 34 (295 mg, 66% yield) was obtained 
as a yellow oil, without the need of chromatographic purification; Rf 0.75 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
34·HCl: brown solid, mp 157159 ºC; IR (ATR) v 35002300 (max at 3471, 3369, 
3203, 3094, 3059, 3023, 2925, 2842, 2584, 2532, +NH, {CH, and CH), 2126 (C{C) 
cm1; 1H NMR (400 MHz, CD3OD) δ 3.03 (s, 3H, NCH3), 3.27 (t, J = 7.2 Hz, 2H, 
1CH2CH2Ph), 3.32 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 3.42 (t, J = 2.4 Hz, 1H, 
propargyl CH), 3.61 (m, 2H, 4CH2CH2N), 4.23 (d, J = 2.4 Hz, 2H, propargyl CH2), 
4.78 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 4.98 (s, +NH), 7.167.30 (complex signal, 
5H, PhCH), 8.22 (s, 1H, 5-H); 13C NMR (100.6 MHz, CD3OD) δ 20.8 (CH2, 
4CH2CH2N), 36.8 (CH2, 1CH2CH2Ph), 40.7 (CH3, NCH3), 46.4 (CH2, 
propargyl CH2), 54.3 (CH2, 1CH2CH2Ph), 54.6 (CH2, 4CH2CH2N), 72.6 (C, 
propargyl C), 81.8 (CH, propargyl CH), 127.1 (CH, C5), 128.2 (CH), 129.8 (4CH) 
(PhCH), 138.0 (C, PhC1), 141.5 (C, C4); HRMS (ESI), calcd for (C16H20N4 + H+) 
269.1761; found 269.1758. 
 
4.1.27. N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-methyl-N-propargylamine 35 
It was prepared as described for 31. From amine 29 (420 mg, 2.08 mmol), Cs2CO3 (676 
mg, 2.07 mmol), and propargyl bromide (80% solution in toluene, 0.31 mL, 2.08 
mmol), and stirring at rt for 3 h, an oily residue (451 mg) was obtained and subjected to 
purification through column chromatography (4060 µm silica gel, CH2Cl2 / MeOH 
mixtures, gradient elution). On elution with CH2Cl2 / MeOH 98:2, propargylamine 35 
(195 mg, 39% yield) was isolated as a colorless oil; Rf 0.48 (CH2Cl2 / MeOH 9.75:0.25). 
35·HCl: pale brown solid, mp 121123 ºC; IR (ATR) v 35002300 (max at 3193, 3126, 
2976, 2961, 2692, 2578, +NH, {CH, and CH), 2118 (C{C) cm1; 1H NMR (400 
MHz, CD3OD) δ 2.96 (s, 3H, NCH3), 3.40 (t, J = 2.8 Hz, 1H, propargyl CH), 4.15 (d, 
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J = 2.8 Hz, 2H, propargyl CH2), 4.57 (s, 2H, 4CH2N), 4.86 (s, +NH), 5.66 (s, 2H, 
1CH2Ph), 7.327.41 (complex signal, 5H, PhCH), 8.27 (s, 1H, 5-H); 13C NMR 
(100.6 MHz, CD3OD) δ 40.2 (CH3, NCH3), 45.7 (CH2, propargyl CH2), 50.3 (CH2, 
4CH2N), 55.1 (CH2, 1CH2Ph), 72.9 (C, propargyl C), 81.6 (CH, propargyl CH), 
128.1 (CH, C5), 129.3 (2CH), 129.7 (CH), 130.1 (2CH) (PhCH), 136.5 (C, PhC1), 
137.9 (C, C4); HRMS (ESI), calcd for (C14H16N4 + H+) 241.1448, found 241.1444. 
 
4.1.28. N-Methyl-N-[(1-phenethyl-1H-1,2,3-triazol-4-yl)methyl]-N-propargylamine 36 
It was prepared as described for 31. From amine 30 (258 mg, 1.19 mmol), Cs2CO3 (199 
mg, 0.61 mmol), and propargyl bromide (80% solution in toluene, 0.17 mL, 1.14 
mmol), and stirring at rt for 3 h, an oily residue (204 mg) was obtained and subjected to 
purification through column chromatography (4060 µm silica gel, CH2Cl2 / EtOAc 
mixtures, gradient elution). On elution with CH2Cl2 / EtOAc 0:100, propargylamine 36 
(63 mg, 22% yield) was isolated as a colorless oil; Rf 0.26 (EtOAc). 
36·HCl: beige sticky solid, IR (ATR) v 35002300 (max at 3400, 3271, 3209, 3023, 
2945, 2501, +NH, {CH, and CH), 2124 (C{C) cm1; 1H NMR (400 MHz, CD3OD) 
δ 2.88 (s, 3H, NCH3), 3.25 (t, J = 7.2 Hz, 2H, 1CH2CH2Ph), 3.42 (t, J = 2.4 Hz, 
1H, propargyl CH), 4.02 (br s, 2H, propargyl CH2), 4.51 (s, 2H, 4CH2N), 4.73 (t, J = 
7.2 Hz, 2H, 1CH2CH2Ph), 4.90 (s, +NH), 7.14 [dm, J = 8.4 Hz, 2H, PhC2(6) H], 
7.177.29 [complex signal, 3H, PhC3(5)H, PhC4H), 8.02 (s, 1H, 5-H); 13C NMR 
(100.6 MHz, CD3OD) δ 37.3 (CH2, 1CH2CH2Ph), 40.1 (CH3, NCH3), 45.5 (CH2, 
propargyl CH2), 50.2 (CH2, 4CH2N), 52.8 (CH2, 1CH2CH2Ph), 72.8 (C, 
propargyl C), 81.7 (CH, propargyl CH), 128.0 (CH), 128.4 (CH) (C5, PhC4), 129.7 
(2CH), 129.9 (2CH) [PhC2(6), PhC3(5)], 137.0 (C, PhC1), 138.6 (C, C4); HRMS 
(ESI), calcd for (C15H18N4 + H+) 255.1604, found 255.1601. 
 
4.1.29. N-(tert-Butoxycarbonyl)-N-[(1-ethyl-5-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-
methylamine 37 
A solution of 17 (420 mg, 1.75 mmol) in anhydrous THF (30 mL) was cooled to ‒78 ºC 
and then treated with n-BuLi (2.5 M solution in hexanes, 1.05 mL, 2.62 mmol) and 
iodomethane (0.43 mL, 980 mg, 6.91 mmol). The reaction mixture was stirred at −78 ºC 
for 1 h, then warmed to rt and stirred an additional 2 h. The resulting solution was 
diluted with H2O (20 mL) and extracted with CH2Cl2 (2 × 40 mL). The combined 
 33 
organic extracts were dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. The resulting residue was washed with pentane (3 × 10 mL) and dried under 
vacuum, to give compound 37 (427 mg, 96% yield) as a colorless oil; Rf 0.57 (CH2Cl2 / 
MeOH 9:1); IR (ATR) ν 1686 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 1.46 [s, 9H, 
C(CH3)3], superimposed in part 1.47 (t, J = 7.6 Hz, 3H, 1CH2CH3), 2.31 (s, 3H, 
5CH3), 2.85 (s, 3H, NCH3), 4.26 (q, J = 7.6 Hz, 2H, 1CH2CH3), 4.48 (s, 2H, 
4CH2N); 13C NMR (100.6 MHz, CDCl3) δ 7.8 (CH3, 5CH3), 15.2 (CH3, 
1CH2CH3), 28.5 [3CH3, C(CH3)3], 34.0 (CH3, NCH3), 42.7 (CH2, 4CH2N), 43.1 
(CH2, 1CH2CH3), 79.8 [C, C(CH3)3], 130.5 (C, C5), 142.0 (C, C4), 156.0 (C, 
NCOO); HRMS (ESI), calcd for (C12H22N4O2 + H+) 255.1816, found 255.1811. 
 
4.1.30. N-(tert-Butoxycarbonyl)-N-[2-(1-ethyl-5-methyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
methylamine 38 
It was prepared as described for 37. From 18 (942 mg, 3.71 mmol), n-BuLi (2.5 M 
solution in hexanes, 2.97 mL, 7.42 mmol) and iodomethane (0.92 mL, 2.10 g, 14.8 
mmol), compound 38 (895 mg, 90% yield) was obtained as a colorless oil; Rf 0.57 
(CH2Cl2 / MeOH 9:1); IR (ATR) ν 1685 (C=O) cm–1; 1H NMR (400 MHz, CDCl3) δ 
1.40 [s, 9H, C(CH3)3], 1.44 (t, J = 7.6 Hz, 3H, 1CH2CH3), 2.20 (s, 3H, 5CH3) , 2.77 
(s, 3H, NCH3), 2.82 (m, 2H, 4CH2CH2N), 3.43 (t, J = 7.2 Hz, 4CH2CH2N), 
4.23 (q, J = 7.6 Hz, 2H, 1CH2CH3); 13C NMR (100.6 MHz, CDCl3) δ 7.7 (CH3, 
5CH3), 15.3 (CH3, 1CH2CH3), 23.7 (br CH2), 24.1 (br CH2) (4CH2CH2N), 28.5 
[3CH3, C(CH3)3], 34.7 (br CH3), 35.0 (br CH3) (NCH3), 43.0 (CH2, 1CH2CH3), 48.7 
(br CH2), 49.2 (br CH2) (4CH2CH2N), 79.4 [C, C(CH3)3], 129.2 (br C), 129.4 (br C) 
(C5), 142.2 (C, C4), 155.7 (C, NCOO); HRMS (ESI), calcd for (C13H24N4O2 + H+) 
269.1972, found 269.1974. 
 
4.1.31. N-(tert-Butoxycarbonyl)-N-methyl-N-{2-[5-methyl-1-(α-methyl)benzyl-1H-1,2,3-
triazol-4-yl]ethyl}amine 39 
It was prepared as described for 37. From 19 (356 mg, 1.13 mmol), n-BuLi (2.5 M 
solution in hexanes, 0.90 mL, 2.25 mmol) and iodomethane (0.28 mL, 638 mg, 4.50 
mmol), compound 39 (306 mg, 79% yield) was obtained as a yellowish oil; IR (ATR) v 
1686, 1681 (C=O) cm1; 1H NMR (400 MHz, CDCl3) δ 1.41 [s, 9H, C(CH3)3], 2.019 [d, 
J = 7.2 Hz, 3H, 1CH(CH3)Ph], 2.023 (s, 3H, 5CH3), 2.76 (s, 3H, NCH3), 2.81 (m, 
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2H, 4CH2CH2N), 3.47 (m, 2H, 4CH2CH2N), 5.49 [q, J = 7.2 Hz, 1H, 
1CH(CH3)Ph], 7.14 [br d, J = 7.2 Hz, PhC2(6)H], 7.247.34 [complex signal, 3H, 
PhC3(5)H, PhC4H]; HRMS (ESI), calcd for   (C19H28N4O2 + H+) 345.2285, found 
345.2285. 
 
4.1.32. N-(tert-Butoxycarbonyl)-N-[(5-butyl-1-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-
methylamine 40 
It was prepared as described for 37. From 21 (945 mg, 4.18 mmol), n-BuLi (2.5 M 
solution in hexanes, 3.36 mL, 8.40 mmol) and 1-bromobutane (1.81 mL, 2.31 g, 16.9 
mmol), compound 40 (1.14 g, 97% yield) was obtained as a yellowish oil; Rf 0.87 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); IR (ATR) v 1689 (C=O) cm1; 1H 
NMR (400 MHz, CDCl3) δ 0.92 (t, J = 7.2 Hz, 3H, 5CH2CH2CH2CH3), 1.35 (tq, J 
= J’ = 7.2 Hz, 2H, 5CH2CH2CH2CH3), superimposed 1.401.52 (2H, 
5CH2CH2CH2CH3), 1.44 [s, 9H, C(CH3)3], 2.69 (m, 2H, 5CH2CH2CH2CH3), 
2.81 (s, 3H, NCH3), 3.93 (s, 3H, 1CH3), 4.49 (s, 2H, 4CH2N); HRMS (ESI), calcd 
for (C14H26N4O2 + H+) 283.2129; found 283.2123. 
 
4.1.33. N-(tert-Butoxycarbonyl)-N-methyl-N-[2-(5-ethyl-1-phenyl-1H-1,2,3-triazol-4-
yl)ethyl]amine 41 
It was prepared as described for 37. From 22 (542 mg, 1.79 mmol), n-BuLi (2.5 M 
solution in hexanes, 1.43 mL, 3.57 mmol) and bromoethane (0.53 mL, 774 mg, 7.10 
mmol), compound 41 (578 mg, 98% yield) was obtained as a yellowish oil; Rf 0.86 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05); IR (ATR) v 1688, 1683 (C=O) cm1; 1H 
NMR (400 MHz, CDCl3) δ 1.05 (t, J = 7.6 Hz, 3H, 5CH2CH3), 1.45 [s, 9H, 
C(CH3)3], 2.70 (m, 2H, 5CH2CH3), 2.88 (s, 3H, NCH3), 2.93 (m, 2H, 
4CH2CH2N), 3.58 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 7.42 [ddm, J = 8.0 Hz, J’ = 
2.4 Hz, 2H, PhC2(6)H], 7.487.57 [complex signal, 3H, PhC3(5)H, PhC4H]; 
HRMS (ESI), calcd for (C18H26N4O2 + H+) 331.2129; found 331.2128. 
 
4.1.34. N-(tert-Butoxycarbonyl)-N-methyl-N-[2-(1-phenyl-5-propyl-1H-1,2,3-triazol-4-
yl)ethyl]amine 42 
It was prepared as described for 37. From 22 (577 mg, 1.91 mmol), n-BuLi (2.5 M 
solution in hexanes, 1.53 mL, 3.82 mmol) and 1-bromopropane (0.69 mL, 934 mg, 7.60 
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mmol), compound 42 (634 mg, 96% yield) was obtained as an orange oil; Rf 0.84 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05); IR (ATR) v 1692, 1682 (C=O) cm1; 1H 
NMR (400 MHz, CDCl3) δ 0.82 (t, J = 7.6 Hz, 3H, 5CH2CH2CH3), superimposed in 
part 1.42 (tt, J = J’ = 7.6 Hz, 2H, 5CH2CH2CH3), 1.46 [s, 9H, C(CH3)3], 2.63 (m, 
2H, 5CH2CH2CH3), 2.88 (s, 3H, NCH3), 2.93 (m, 2H, 4CH2CH2N), 3.59 (t, J 
= 7.2 Hz, 2H, 4CH2CH2N), 7.41 [ddm, J =8.0 Hz, J’ = 2.4 Hz, 2H, PhC2(6)H], 
7.487.56 [complex signal, 3H, PhC3(5)H, PhC4H]; HRMS (ESI), calcd for 
(C19H28N4O2 + H+) 345.2285, found 345.2286. 
 
4.1.35. N-(tert-Butoxycarbonyl)-N-methyl-N-[2-(5-butyl-1-phenyl-1H-1,2,3-triazol-4-
yl)ethyl]amine 43 
It was prepared as described for 37. From 22 (590 mg, 1.95 mmol), n-BuLi (2.5 M 
solution in hexanes, 1.56 mL, 3.90 mmol) and 1-bromobutane (0.84 mL, 1.07 g, 7.82 
mmol), an oily residue (678 mg) was obtained. After column chromatography 
purification of the residue (4060 µm silica gel, CH2Cl2 / 50% aq. NH4OH 100:0.2), 
compound 43 (300 mg, 43% yield) was isolated as a yellow oil; Rf 0.82 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9:1:0.05); IR (ATR) v 1692 (C=O) cm1; 1H NMR (400 MHz, 
CDCl3) δ 0.79 (t, J = 7.2 Hz, 3H, 5CH2CH2CH2CH3), 1.21 (tq, J = J’ = 7.2 Hz, 
2H, 5CH2CH2CH2CH3), 1.35 (m, 2H, 5CH2CH2CH2CH3), 1.45 [s, 9H, 
C(CH3)3], 2.65 (m, 2H, 5CH2CH2CH2CH3), 2.87 (s, 3H, NCH3), 2.91 (m, 2H, 
4CH2CH2N), 3.59 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 7.41 [ddm, J = 8.0 Hz, J’ = 
2.4 Hz, 2H, PhC2(6)H], 7.477.56 [complex signal, 3H, PhC3(5)H, PhC4H]; 
HRMS (ESI), calcd for (C20H30N4O2 + H+) 359.2442, found 359.2438. 
 
4.1.36. N-[(1-Ethyl-5-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 44 
It was prepared as described for 25. From 37 (370 mg, 1.46 mmol) and H3PO4 (85% 
purity, 2.52 mL, 21.9 mmol), and stirring at rt for 4 h, amine 44 (205 mg, 91% yield) 
was obtained as a colorless oil; Rf 0.11 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
44·HCl: beige sticky solid, IR (ATR) ν 35002400 (max at 3390, 2925, 2868, 2837, 
2757, 2697, 2546, 2440, +NH and CH) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.48 (t, 
J = 7.2 Hz, 3H, 1CH2CH3), 2.41 (s, 3H, 5CH3), 2.76 (s, 3H, NCH3), 4.28 (s, 2H, 
4CH2N), 4.38 (q, J = 7.2 Hz, 2H, 1CH2CH3), 4.87 (s, +NH2); 13C NMR (100.6 
MHz, CD3OD) δ 7.7 (CH3, 5CH3), 15.2 (CH3, 1CH2CH3), 33.1 (CH3, NCH3), 43.6 
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(CH2), 44.4 (CH2) (1CH2CH3, 4CH2N), 134.7 (C, C5), 136.8 (C, C4); HRMS 
(ESI), calcd for (C7H14N4 + H+) 155.1291, found 155.1288. 
 
4.1.37. N-[2-(1-Ethyl-5-methyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 45 
It was prepared as described for 25. From 38 (890 mg, 3.32 mmol) and H3PO4 (85% 
purity, 5.70 mL, 49.4 mmol), and stirring at rt for 1.5 h, amine 45 (495 mg, 89% yield) 
was obtained as a colorless oil; Rf 0.10  (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
45·HCl: beige sticky solid, IR (ATR) ν 35002300 (max at 3374, 2981, 2937, 2746, 
2692, 2449, 2359, +NH and CH st) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.49 (t, J = 
7.2 Hz, 3H, 1CH2CH3), 2.38 (s, 3H, 5CH3), 2.76 (s, 3H, NCH3), 3.09 (t, J = 7.2 
Hz, 2H, 4CH2CH2N), 3.34 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.40 (q, J = 7.2 Hz, 
2H, 1CH2CH3), 4.86 (s, +NH2); 13C NMR (100.6 MHz, CD3OD) δ 7.6 (CH3, 5CH3), 
15.0 (CH3, 1CH2CH3), 22.2 (CH2, 4CH2CH2N), 33.7 (CH3, NCH3), 44.9 (CH2, 
1CH2CH3), 49.0 (4CH2CH2N), 133.4 (C, C5), 140.1 (C, C4); HRMS (ESI), calcd 
for (C8H16N4 + H+) 169.1448, found 169.1452. 
 
4.1.38. N-Methyl-N-{2-[5-methyl-1-(α-methyl)benzyl-1H-1,2,3-triazol-4-yl]ethyl}amine 
46 
It was prepared as described for 25. From 39 (306 mg, 0.89 mmol) and H3PO4 (85% 
purity, 1.60 mL, 13.9 mmol), amine 46 (215 mg, quantitative yield) was obtained as a 
yellow oil; Rf 0.33 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
46·HCl: yellow sticky solid, IR (ATR) v 34002400 (max at 3373, 2950, 2709, 2434, 
+NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 2.01 [d, J = 7.2 Hz, 3H, 
1CH(CH3)Ph], 2.30 (s, 3H, 5-CH3), 2.76 (s, 3H, NCH3), 3.19 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 3.36 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.94 (s, +NH2), 5.93 (q, J = 
7.2 Hz, 1H, 1CH(CH3)Ph], 7.30 [dm, J = 8.4 Hz, 2H, PhC2(6)-H], 7.367.42 
[complex signal, 3H, PhC3(5)-H, PhC4-H]; 13C NMR (100.6 MHz, CD3OD) δ 8.2 
(CH3, 5CH3), 21.7 [CH3, 1CH(CH3)Ph], 21.9 (CH2, 4CH2CH2N), 33.7 (CH3, 
NCH3), 53.8 (CH2, 4CH2CH2N), 61.5 [CH, 1CH(CH3)Ph], 127.5 (2CH), 129.7 
(CH), 130.2 (2CH) (PhCH), 135.6 (C, PhC1), 139.3 (C, C5), 140.5 (C, C4); HRMS 
(ESI), calcd for (C14H20N4 + H+) 245.1761, found 245.1762. 
 
4.1.39. N-[(5-Butyl-1-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 47 
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It was prepared as described for 25. From 40 (954 mg, 3.38 mmol) and H3PO4 (85% 
purity, 5.84 mL, 50.7 mmol), amine 47 (620 mg, quantitative yield) was obtained as a 
yellow oil; Rf 0.06 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
47·HCl: beige sticky solid, IR (ATR) v 34002500 (max at 3372, 2957, 2930, 2863, 
2711, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 0.97 (t, J = 7.2 Hz, 3H, 
5CH2CH2CH2CH3), 1.42 (tq, J = J’ = 7.2 Hz, 2H, 5CH2CH2CH2CH3), 1.58 
(tt, J = 7.6 Hz, J’ = 7.2 Hz, 2H, 5CH2CH2CH2CH3), 2.79 (s, 3H, NCH3), 2.87 (t, 
J = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 4.05 (s, 3H, 1CH3), 4.31 (s, 2H, 4CH2N), 
5.06 (s, +NH2); 13C NMR (100.6 MHz, CD3OD) δ 14.0 (CH3, 5CH2CH2CH2CH3), 
22.9 (CH2), 23.4 (CH2) (5CH2CH2CH2CH3), 31.6 (CH2, 5CH2CH2CH2CH3), 
33.3 (CH3, NCH3), 35.5 (CH3, 1CH3), 43.5 (CH2, 4CH2N), 136.5 (C, C5), 139.3 
(C, C4); HRMS (ESI), calcd for (C9H18N4 + H+) 183.1604, found 183.1599. 
 
4.1.40. N-Methyl-N-[2-(5-ethyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]amine 48 
It was prepared as described for 25. From 41 (517 mg, 1.57 mmol) and H3PO4 (85% 
purity, 2.68 mL, 23.2 mmol), and stirring at rt for 3 h, an orange oil (435 mg) was 
obtained and purified through column chromatography (4060 µm silica gel, CH2Cl2 / 
MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 
50% aq. NH4OH 98:2:0.2 to 96:4:0.2, amine 48 (322 mg, 89% yield) was obtained as a 
yellowish oil; Rf 0.51 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
48·HCl: yellow sticky solid, IR (ATR) v 34002300 (max at 3380, 2964, 2930, 2873, 
2741, 2434, 2351, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 1.05 (t, J = 
7.6 Hz, 3H, 5CH2CH3), superimposed in part 2.80 (q, J = 7.6 Hz, 2H, 5CH2CH3), 
2.81 (s, 3H, NCH3), 3.20 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 3.45 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 4.89 (s, +NH2), 7.53 [ddm, J = 7.6 Hz, J’ = 2.0 Hz, 2H, PhC2(6)H], 
7.627.67 [complex signal, 3H, PhC3(5)H, PhC4H]; 13C NMR (100.6 MHz, 
CD3OD) δ 13.4 (CH3, 5CH2CH3), 16.9 (CH2, 5CH2CH3), 22.5 (CH2, 
4CH2CH2N), 33.9 (CH3, NCH3), 49.3 (CH2, 4CH2CH2N), 126.8 (2CH), 130.9 
(2CH), 131.4 (CH) (PhCH), 137.5 (C, PhC1), 139.1 (C, C5), 140.5 (C, C4); HRMS 
(ESI), calcd for (C13H18N4 + H+) 231.1604; found 231.1607. 
 
4.1.41. N-Methyl-N-[2-(1-phenyl-5-propyl-1H-1,2,3-triazol-4-yl)ethyl]amine 49 
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It was prepared as described for 25. From 42 (573 mg, 1.66 mmol) and H3PO4 (85% 
purity, 2.85 mL, 24.7 mmol), and stirring at rt for 3 h, an orange oil (564 mg) was 
obtained and purified through column chromatography (4060 µm silica gel, CH2Cl2 / 
MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 
50% aq. NH4OH 99:1:0.2 to 95:5:0.2, amine 49 (270 mg, 67% yield) was obtained as a 
yellowish oil; Rf 0.52 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
49·HCl: yellow sticky solid, IR (ATR) v 34002400 (max at 3350, 2960, 2935, 2863, 
2721, 2430, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 0.81 (t, J = 7.6 Hz, 
3H, 5CH2CH2CH3), 1.42 (tq, J = J’ = 7.6 Hz, 2H 5CH2CH2CH3), 2.74 (t, J = 
7.6 Hz, 2H, 5CH2CH2CH3), 2.80 (s, 3H, NCH3), 3.16 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 3.43 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.85 (s, +NH2), 7.487.65 
(complex signal, 5H, PhCH); 13C NMR (100.6 MHz, CD3OD) δ 13.9 (CH3, 
5CH2CH2CH3), 22.6 (CH2, 4CH2CH2N), 22.9 (CH2, 5CH2CH2CH3), 25.2 
(CH2, 5CH2CH2CH3), 33.8 (CH3, NCH3), 49.4 (CH2, 4CH2CH2N) 126.8 
(2CH), 130.9 (2CH), 131.3 (CH) (PhCH), 137.4 (C, PhC1), 137.7 (C, C5), 141.3 (C, 
C4); HRMS (ESI), calcd for (C14H20N4 + H+) 245.1761, found 245.1761. 
 
4.1.42. N-Methyl-N-[2-(5-butyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]amine 50 
It was prepared as described for 25. From 43 (265 mg, 0.74 mmol) and H3PO4 (85% 
purity, 1.27 mL, 11.0 mmol), and stirring at rt for 3 h, amine 50 (175 mg, 92% yield) 
was obtained as a yellowish oil; Rf 0.54 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
50·HCl: yellow oil, IR (ATR) v 34002400 (max at 3389, 2954, 2919, 2868, 2755, 
2444, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 0.80 (t, J = 7.6 Hz, 3H, 
5CH2CH2CH2CH3), 1.22 (tq, J = J’ = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 1.38 
(tt, J = J’ = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 2.77 (t, J = 7.6 Hz, 2H, 
5CH2CH2CH2CH3), 2.81 (s, 3H, NCH3), 3.15 (t, J = 7.2 Hz, 2H, 
4CH2CH2N), 3.44 (t, J = 7.2 Hz, 2H, 4CH2CH2N), 4.85 (s, +NH2), 7.51 [dm, J = 
8.0 Hz, 2H, PhC2(6)H], 7.617.66 [complex signal, 3H, PhC3(5)H, PhC4H]; 
13C NMR (100.6 MHz, CD3OD) δ 13.8 (CH3, 5CH2CH2CH2CH3), 22.6 (CH2, 
4CH2CH2N), 23.0 (CH2), 23.2 (CH2) (5CH2CH2CH2CH3), 31.6 (CH2, 
5CH2CH2CH2CH3), 33.8 (CH3, NCH3), 49.4 (CH2, 4CH2CH2N), 126.8 
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(2CH), 130.9 (2CH), 131.3 (CH) (PhCH), 137.5 (C, PhC1), 137.7 (C, C5), 141.2 (C, 
C4); HRMS (ESI), calcd for (C15H22N4 + H+) 259.1917, found 259.1922. 
 
4.1.43. N-[(1-Ethyl-5-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-methyl-N-propargylamine 
51 
It was prepared as described for 31. From amine 44 (128 mg, 0.83 mmol), Cs2CO3 (270 
mg, 0.83 mmol), and propargyl bromide (80% solution in toluene, 0.12 mL, 0.81 
mmol), and stirring at 0 ºC for 2 h, propargylamine 51 (96 mg, 62% yield) was obtained 
as a yellow oil, without the need of chromatographic purification; Rf 0.43 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9:1:0.05). 
51·HCl: yellow sticky solid, IR (ATR) ν 35002300 (max at 3386, 3197, 2938, 2496, 
2352, +NH, {CH, and CH), 2123 (C{C) cm–1; 1H NMR (400 MHz, CD3OD) δ 1.50 
(t, J = 7.2 Hz, 3H, 1CH2CH3), 2.45 (s, 3H, 5CH3), 3.00 (s, 3H, NCH3), 3.44 (t, J = 
2.4 Hz, 1H, propargyl CH), 4.17 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.39 (q, J = 7.2 
Hz, 2H, 1CH2CH3), 4.52  (s, 2H, 4CH2N), 4.84 (s, +NH); 13C NMR (100.6 MHz, 
CD3OD) δ 8.0 (CH3, 5CH3), 15.2 (CH3, 1CH2CH3), 40.3 (CH3, NCH3), 44.5 (CH2, 
1CH2CH3), 45.6 (CH2, propargyl CH2), 49.8 (CH2, 4CH2N), 73.1 (C, propargyl 
C), 81.5 (CH, propargyl CH), 135.1 (C, C5), 136.3 (C, C4); HRMS (ESI), calcd for 
(C10H16N4 + H+) 193.1448, found 193.1450. Note: From amine 44 (117 mg, 0.76 mmol), Cs2CO3 (362 mg, 1.11 mmol), and 
propargyl bromide (80% solution in toluene, 0.16 mL, 1.08 mmol), and stirring at rt 
overnight, an oily residue was obtained and purified through column chromatography 
(4060 µm silica gel, CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). 
On elution with CH2Cl2 / MeOH / 50% aq. NH4OH 99:1:0.2 to 98:2:0.2, 
propargylamine 51 (15 mg, 10% yield) was isolated as a colorless oil. On elution with 
CH2Cl2 / MeOH / 50% aq. NH4OH 98:2:0.2, slightly impure N-[(1-ethyl-5-methyl-1H-
1,2,3-triazol-4-yl)methyl]-N-methyl-N,N-dipropargylammonium bromide (223 mg) was 
isolated as a brown oil; Rf 0. 04 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
A solution of the dipropargylated byproduct (223 mg) in CH2Cl2 (20 mL) was filtered 
through a PTFE filter (0.2 µm) and evaporated under reduced pressure. The resulting 
residue was washed with pentane (3 × 2 mL) to give, after drying under standard 
conditions, the analytical sample of the dipropargylated byproduct (213 mg) as a 
brownish oil; IR (ATR) ν  3207 ({CH), 2124 (C{C st) cm–1; 1H NMR (400 MHz, 
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CDCl3) δ 1.53 (t, J = 7.6 Hz, 3H, 1CH2CH3), 2.73 (s, 3H, 5CH3), 2.85 (t, J = 2.4 
Hz, 2H, 2 propargyl CH), 3.42 (s, 3H, NCH3), 4.34 (q, J = 7.6 Hz, 2H, 1CH2CH3), 
4.83 (dd, J = 16.0 Hz, J’ = 2.4 Hz, 2H), 4.91 (dd, J = 16.0 Hz, J’ = 2.4 Hz, 2H) (2 
propargyl CH2), 5.34 (s, 2H, 4CH2N); 13C NMR (100.6 MHz, CDCl3) δ 8.8 (CH3, 
5CH3), 14.8 (CH3, 1CH2CH3), 43.6 (CH2, 1CH2CH3), 47.2 (CH3, NCH3), 51.8 
(2CH2, 2 propargyl CH2), 55.7 (CH2, 4CH2N), 70.9 (2C, 2 propargyl C), 82.2 (2CH, 
2 propargyl CH), 132.5 (C, C5), 136.5 (C, C4); HRMS (ESI), calcd for (C13H19N4+) 
231.1604, found 231.1613. 
 
4.1.44. N-[2-(1-Ethyl-5-methyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methyl-N-
propargylamine 52 
It was prepared as described for 31. From amine 45 (490 mg, 2.91 mmol), Cs2CO3 (952 
mg, 2.92 mmol), and propargyl bromide (80% solution in toluene, 0.43 mL, 2.89 
mmol), and stirring at 0 ºC for 2.5 h, propargylamine 52 (319 mg, 54% yield) was 
obtained as a yellow oil, without the need of chromatographic purification; Rf 0.59 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
52·HCl: yellow sticky solid, IR (ATR) ν 35002300 (max at 3406, 3181, 2981, 2932, 
2583, 2518, 2461, 2408, 2366, +NH, {CH, and CH), 2123 (C{C) cm–1; 1H NMR 
(400 MHz, CD3OD) δ 1.56 (t, J = 7.2 Hz, 3H, 1CH2CH3), 2.50 (s, 3H, 5CH3), 3.08 
(s, 3H, NCH3), 3.35 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 3.45 (t, J = 2.8 Hz, 1H, 
propargyl CH), 3.63 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 4.28 (d, J = 2.8 Hz, 2H, 
propargyl CH2), 4.51 (q, J = 7.2 Hz, 2H, 1CH2CH3), 4.94 (s, +NH); 13C NMR (100.6 
MHz, CD3OD) δ 8.0 (CH3, 5CH3), 14.4 (CH3, 1CH2CH3), 20.0 (CH2, 
4CH2CH2N), 40.7 (CH3, NCH3), 46.3 (CH2, propargyl CH2), 46.4 (CH2, 
1CH2CH3), 54.0 (CH2, 4CH2CH2N), 72.5 (C, propargyl C), 81.9 (CH, propargyl 
CH), 136.3 (C, C5), 137.8 (C, C4); HRMS (ESI), calcd for (C11H18N4 + H+) 207.1604, 
found 207.1609. 
 
4.1.45. N-Methyl-N-{2-[5-methyl-1-(α-methyl)benzyl-1H-1,2,3-triazol-4-yl]ethyl}-N-
propargylamine 53 
It was prepared as described for 31. From amine 46 (234 mg, 0.93 mmol), Cs2CO3 (0.30 
g, 0.92 mmol), and propargyl bromide (80% solution in toluene, 0.10 mL, 0.67 mmol), 
and stirring at at 0 °C for 30 min and at rt for an additional 3 h, an orange oily residue 
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(263 mg) was obtained and purified through column chromatography (4060 µm silica 
gel, CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with 
CH2Cl2 / MeOH / 50% aq. NH4OH 99.97:0.03:0.2, propargylamine 53 (100 mg, 53% 
yield) was obtained as a yellow oil; Rf 0.45 (CH2Cl2 / MeOH / 50% aq. NH4OH 
9:1:0.05). 
53·HCl: beige sticky solid, IR (ATR) v 34002300 (max at 3386, 3209, 2936, 2351, 
+NH, {CH, and CH), 2118 (C{C) cm1; 1H NMR (400 MHz, CD3OD) δ 2.01 [d, J = 
6.8 Hz, 3H, 1CH(CH3)Ph], 2.26 (s, 3H, 5CH3), 3.06 (s, 3H, NCH3), 3.22 (t, J = 8.0 
Hz, 2H, 4CH2CH2N), 3.42 (t, J = 2.4 Hz, 1H, propargyl CH), 3.59 (t, J = 8.0 Hz, 
2H, 4CH2CH2N), 4.25 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.89 (s, +NH), 5.86 [q, J 
= 6.8 Hz, 1H, 1CH(CH3)Ph], 7.247.40 (complex signal, 5H, PhCH); 13C NMR 
(100.6 MHz, CD3OD) δ 8.1 (CH3, 5CH3), 20.5 (CH2, 4CH2CH2N), 22.0 [CH3, 
1CH(CH3)Ph], 40.7 (CH3,  NCH3), 46.3 (CH2, propargyl CH2), 54.7 (CH2, 
4CH2CH2N), 61.0 [CH, 1CH(CH3)Ph], 72.6 (C, propargyl C), 81.7 (CH, 
propargyl CH), 127.4 (2CH), 129.6 (CH), 130.2 (2CH) (PhCH), 134.5 (C, PhC1), 
139.6 (C, C5), 141.1 (C, C4); HRMS (ESI), calcd for (C17H22N4 + H+) 283.1917, found 
283.1923. 
 
4.1.46. N-[(5-Butyl-1-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-methyl-N-propargylamine 
54 
It was prepared as described for 31. From amine 47 (529 mg, 2.90 mmol), Cs2CO3 (946  
mg, 2.90 mmol), and propargyl bromide (80% solution in toluene, 0.44 mL, 2.96 
mmol), and stirring at rt for 3.5 h, propargylamine 54 (418 mg, 65% yield) was obtained 
as a yellow oil, without the need of chromatographic purification; Rf 0.29 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
54·HCl: brown sticky solid, IR (ATR) v 35002400 (max at 3411, 3219, 2955, 2930, 
2863, 2491, +NH, {CH, and CH), 2121 (C{C) cm1; 1H NMR (400 MHz, CD3OD) 
δ 0.98 (t, J = 7.6 Hz, 3H, 5CH2CH2CH2CH3), 1.43 (tq, J = J’ = 7.6 Hz, 2H, 
5CH2CH2CH2CH3), 1.59 (tt, J = J’ = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 2.88 (t, 
J = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 3.03 (s, 3H, NCH3), 3.47 (t, J = 2.4 Hz, 1H, 
propargyl CH), 4.06 (s, 3H, 1CH3), 4.22 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.55 (s, 
2H, 4CH2N), 4.92 (s, +NH); 13C NMR (100.6 MHz, CD3OD) δ 14.1 (CH3, 
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5CH2CH2CH2CH3), 23.0 (CH2), 23.4 (CH2) (5CH2CH2CH2CH3), 31.6 (CH2, 
5CH2CH2CH2CH3), 35.5 (CH3, 1CH3), 40.5 (CH3, NCH3), 45.6 (CH2, propargyl 
CH2), 49.5 (CH2, 4CH2N), 73.2 (C, propargyl C), 81.6 (CH, propargyl CH), 134.9 
(C, C5), 140.5 (C, C4); HRMS (ESI), calcd for (C12H20N4 + H+) 221.1761, found 
221.1762. 
 
4.1.47. N-Methyl-N-[2-(5-ethyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
propargylamine 55 
It was prepared as described for 31. From amine 48 (260 mg, 1.13 mmol), Cs2CO3 (0.37 
g, 1.14 mmol), and propargyl bromide (80% solution in toluene, 0.13 mL, 0.87 mmol), 
and stirring at 0 ºC for 30 min and at rt for an additional 3 h, an orange oil (333 mg) was 
obtained and purified through column chromatography (4060 µm silica gel, CH2Cl2 / 
MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / MeOH / 
50% aq. NH4OH 99.9:0.1:0.2, propargylamine 55 (222 mg, 95% yield) was obtained as 
a yellow oil; Rf 0.59 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
55·HCl: yellow sticky solid, IR (ATR) v 34002300 (max at 3395, 3193, 3059, 2958, 
2925, 2573, 2518, 2459, 2397, +NH, {CH, and CH), 2123 (C{C) cm1; 1H NMR 
(400 MHz, CD3OD) δ 1.06 (t, J = 7.6 Hz, 3H, 5CH2CH3), 2.81 (q, J = 7.6 Hz, 2H, 
5CH2CH3), 3.11 (s, 3H, NCH3), 3.27 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 3.45 (t, J 
= 2.8 Hz, 1H, propargyl CH), 3.70 (m, 2H, 4CH2CH2N), 4.31 (d, J = 2.8 Hz, 2H, 
propargyl CH2), 4.88 (s, +NH), 7.53 [ddm, J = J’ = 7.6 Hz, 2H, PhC2(6)H], 
7.627.67 [complex signal, 3H, PhC3(5)H, PhC4H]; 13C NMR (100.6 MHz, 
CD3OD) δ 13.4 (CH3, 5CH2CH3), 16.9 (CH2, 5CH2CH3),  21.1 (CH2, 
4CH2CH2N), 40.8 (CH3, NCH3), 46.3 (CH2, propargyl CH2), 55.3 (CH2, 
4CH2CH2N), 72.7 (C, propargyl C), 81.7 (CH, propargyl CH), 126.7 (2CH), 130.9 
(2CH), 131.4 (CH) (PhCH), 137.6 (C, PhC1), 139.1 (C, C5), 140.2 (C, C4); HRMS 
(ESI), calcd for (C16H20N4 + H+) 269.1761; found 269.1766. 
 
4.1.48. N-Methyl-N-[2-(1-phenyl-5-propyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
propargylamine 56 
It was prepared as described for 31. From amine 49 (168 mg, 0.69 mmol), Cs2CO3 (0.22 
g, 0.68 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), 
and stirring at 0 ºC for 30 min and at rt for an additional 3 h, an oily residue (278 mg) 
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was obtained and purified through column chromatography (4060 µm silica gel, 
CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / 
MeOH / 50% aq. NH4OH 98:2:0.2, propargylamine 56 (117 mg, 88% yield) was 
obtained as a yellow oil; Rf 0.84 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
56·HCl: orange sticky solid, IR (ATR) v 35002300 (max at 3400, 3197, 2958, 2930, 
2873, 2354, +NH, {CH, and CH), 2121 (C{C) cm1; 1H NMR (400 MHz, CD3OD) 
δ 0.83 (t, J = 7.6 Hz, 3H, 5CH2CH2CH3), 1.44 (tq, J = J’ = 7.6 Hz, 2H, 
5CH2CH2CH3), 2.77 (t, J = 7.6 Hz, 2H, 5CH2CH2CH3), 3.11 (s, 3H, NCH3), 
3.22 (t, J = 7.6 Hz, 2H, 4CH2CH2N), 3.45 (t, J = 2.4 Hz, 1H, propargyl CH), 3.70 
(m, 2H, 4CH2CH2N), 4.31 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.85 (s, +NH), 7.52 
(m, 2H), 7.627.66 (complex signal, 3H) (PhCH); 13C NMR (100.6 MHz, CD3OD) δ 
13.9 (CH3, 5CH2CH2CH3), 21.1 (CH2, 4CH2CH2N), 22.8 (CH2, 
5CH2CH2CH3), 25.2 (CH2, 5CH2CH2CH3), 40.9 (CH3, NCH3), 46.3 (CH2, 
propargyl CH2), 55.3 (CH2, 4CH2CH2N), 72.7 (C, propargyl C), 81.7 (CH, 
propargyl CH), 126.8 (2CH), 130.9 (2CH), 131.4 (CH) (PhCH), 137.6 (C), 137.7 (C) 
(C5, PhC1), 140.7 (C, C4); HRMS (ESI), calcd for (C17H22N4 + H+) 283.1917, found 
283.1923. 
 
4.1.49. N-Methyl-N-[2-(5-butyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]-N-
propargylamine 57 
It was prepared as described for 31. From amine 50 (157 mg, 0.61 mmol), Cs2CO3 (0.22 
g, 0.68 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), 
and stirring at 0 ºC for 30 min and at rt for an additional 3 h, an oily residue (172 mg) 
was obtained and purified through column chromatography (4060 µm silica gel, 
CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution with CH2Cl2 / 
MeOH / 50% aq. NH4OH 100:0:0.2 to 99:1:0.2, propargylamine 57 (164 mg, 91% 
yield) was obtained as a yellow oil; Rf 0.86 (CH2Cl2 / MeOH / 50% aq. NH4OH 
9:1:0.05). 
57·HCl: yellow sticky solid, IR (ATR) v 35002300 (max at 3426, 3209, 2962, 2929, 
2869, 2352, +NH, {CH, and CH), 2120 (C{C) cm1; 1H NMR (400 MHz, CD3OD) 
δ 0.80 (t, J = 7.6 Hz, 3H, 5CH2CH2CH2CH3), 1.23 (tq, J = J’ = 7.6 Hz, 2H, 
5CH2CH2CH2CH3), 1.39 (tt, J = J’ = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 2.78 (t, 
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J = 7.6 Hz, 2H, 5CH2CH2CH2CH3), 3.11 (s, 3H, NCH3), 3.22 (t, J = 7.6 Hz, 2H, 
4CH2CH2N), 3.46 (t, J = 2.4 Hz, 1H, propargyl CH), 3.69 (m, 2H, 4CH2CH2N), 
4.30 (d, J = 2.4 Hz, 2H, propargyl CH2), 4.85 (s, +NH), 7.50 (m, 2H), 7.627.66 
(complex signal, 2H) (PhCH); 13C NMR (100.6 MHz, CD3OD) δ 13.8 (CH3, 
5CH2CH2CH2CH3), 21.1 (CH2, 4CH2CH2N), 23.1 (CH2), 23.2 (CH2) 
(5CH2CH2CH2CH3), 31.6 (CH2, 5CH2CH2CH2CH3), 40.9 (CH3, NCH3), 
46.3 (CH2, propargyl CH2), 55.3 (CH2, 4CH2CH2N), 72.7 (C, propargyl C), 81.7 
(CH, propargyl CH), 126.8 (2CH), 130.9 (2CH), 131.4 (CH) (PhCH), 137.69 (C), 
137.72 (C) (C5, PhC1), 140.6 (C, C4); HRMS (ESI), calcd for (C18H24N4 + H+) 
297.2074, found 297.2085. 
 
4.1.50. 3-[3-(Trimethylsilyl)-2-propynyl]benzonitrile 61 
A solution of trimethylsilylacetylene (1.59 mL, 1.11 g, 11.3 mmol) in anhydrous THF 
(22 mL) was cooled to −78 ºC, treated dropwise with n-BuLi (2.5 M solution in 
hexanes, 4.59 mL, 11.5 mmol), and stirred at −78 ºC for 30 min. A solution of ZnBr2 
(2.59 g, 11.5 mmol) in anhydrous THF (8 mL) was then added and the resulting mixture 
was warmed to 0 ºC. 3-Bromomethylbenzonitrile, 58 (1.50 g, 7.65 mmol), and 
Pd(PPh3)2Cl2 (290 mg, 0.41 mmol) were added and the reaction mixture was stirred at rt 
overnight. The reaction mixture was cooled to 0 ºC, treated with 1 N HCl (20 mL), and 
extracted with EtOAc (2 × 30 mL). The combined organic extracts were washed with 
sat. aq. NaHCO3  (20 mL), dried over anhydrous Na2SO4, and evaporated under reduced 
pressure to give a residue (2.02 g), which was purified through column chromatography 
(4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On elution with 
hexane / EtOAc 95:5, compound 61 (1.03 g, 63% yield) was isolated as a colorless oil; 
Rf 0.73 (hexane / EtOAc 8:2); 2230 (C{N), 2178 (C{C) cm1; 1H NMR (400 MHz, 
CDCl3) δ 0.20 [s, 9H, Si(CH3)3], 3.68 (s, 2H, 1’-H2), 7.42 (dd, J = J’ = 7.6 Hz, 1H, 5-
H), 7.53 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H) (4-H, 6-H), 7.65 (br s, 1H, 2-H); 
13C NMR (100.6 MHz, CDCl3) δ 0.2 [3CH3, Si(CH3)3], 26.0 (CH2, C1’), 88.6 (C, C3’), 
102.4 (C, C2’), 112.7 (C, C1), 118.9 (C, CN), 129.4 (CH), 130.6 (CH), 131.6 (CH), 
132.5 (CH) (phenylene CH), 138.1 (C, C3); HRMS (ESI), calcd for (C13H15NSi + H+) 
214.1047, found 214.1048. 
 
4.1.51. 4-[3-(Trimethylsilyl)-2-propynyl]benzonitrile 62 
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It was prepared as described for 61. From trimethylsilylacetylene (1.06 mL, 737 mg, 
7.50 mmol), n-BuLi (2.5 M solution in hexanes, 3.06 mL, 7.65 mmol), ZnBr2 (1.72 g, 
7.64 mmol), 4-bromomethylbenzonitrile, 59 (1.00 g, 5.10 mmol), and Pd(PPh3)2Cl2 (183 
mg, 0.26 mmol), a residue (1.38 g) was obtained and purified through column 
chromatography (4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On 
elution with hexane / EtOAc 90:10, compound 62 (900 mg, 83% yield) was isolated as 
a colorless oil; Rf 0.77 (hexane / EtOAc 8:2); IR (ATR) v 2230 (C{N), 2178 (C{C) 
cm1; 1H NMR (400 MHz, CDCl3) δ 0.19 [s, 9H, Si(CH3)3], 3.70 (s, 2H, 1’-H2), 7.46 
[dm, J = 8.4 Hz, 2H, 3(5)-H], 7.61 [dm, J = 8.4 Hz, 2H, 2(6)-H]; 13C NMR (100.6 MHz, 
CDCl3) δ 0.1 [3CH3, Si(CH3)3], 26.5 (CH2, C1’), 88.6 (C, C3’), 102.3 (C, C2’), 110.8 
(C, C1), 119.0 (C, CN), 128.8 [2CH, C3(5)], 132.5 [2CH, C2(6)], 142.1 (C, C4); HRMS 
(ESI), calcd for (C13H15NSi + H+) 214.1047; found 214.1048. 
 
4.1.52. 4-[3-(Trimethylsilyl)-2-propynyl]phenylacetonitrile 63 
It was prepared as described for 61. From trimethylsilylacetylene (5.20 mL, 3.61 g, 36.8 
mmol), n-BuLi (2.5 M solution in hexanes, 15.0 mL, 37.5 mmol), ZnBr2 (8.46 g, 37.6 
mmol), 4-(bromomethyl)phenylacetonitrile, 60 (5.26 g, 25.0 mmol), and Pd(PPh3)2Cl2 
(940 mg, 1.34 mmol), a residue (7.12 g) was obtained and purified through column 
chromatography (4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On 
elution with hexane / EtOAc 95:5, compound 63 (2.50 g, 44% yield) was isolated as a 
yellow oil; Rf 0.50 (hexane / EtOAc 8:2); IR (ATR) v 2344 (C{N), 2144 (C{C) cm1; 
1H NMR (400 MHz, CDCl3) δ 0.19 [s, 9H, Si(CH3)3], 3.65 (s, 2H, 1’-H2), 3.73 (s, 2H, 
1CH2CN), 7.28 (br d, J = 8.4 Hz, 2H), 7.36 (br d, J = 8.4 Hz, 2H) (PhCH); 13C 
NMR (100.6 MHz, CDCl3) δ 0.03 [3CH3, Si(CH3)3], 23.3 (CH2, 1CH2CN), 25.8 
(CH2, C1’), 87.3 (C, C3’), 103.6 (C, C2’), 117.8 (C, CN), 128.1 (2CH), 128.6 (2CH) 
(PhCH), 128.2 (C, PhC1), 136.5 (C, PhC4); HRMS (ESI), calcd for (C14H17NSi + 
H+) 228.1203; found 228.1203. 
 
4.1.53. 3-(2-Propynyl)benzonitrile 64 
To a solution of 61 (1.60 g, 7.51 mmol) in CH2Cl2 (70 mL), a solution of AgOTf (193 
mg, 0.75 mmol) in MeOH / H2O 11:1 (50 mL) was added. The reaction mixture was 
stirred at rt for 7 h, treated with an additional amount of AgOTf (386 mg, 1.50 mmol), 
and stirred at rt overnight. The resulting mixture was diluted with sat. aq. NH4Cl (50 
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mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic extracts were 
washed with H2O (50 mL), dried over anhydrous Na2SO4, and evaporated under 
reduced pressure to give a crude (944 mg), which was purified through column 
chromatography (4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On 
elution with hexane / EtOAc 95:5, alkyne 64 (690 mg, 65% yield) was isolated as a 
white solid; Rf 0.72 (hexane / EtOAc 8:2), mp 6365 ºC; IR (ATR) v 3247 ({CH), 
2231 (C{N, C{C) cm1; 1H NMR (400 MHz, CDCl3) δ 2.26 (t, J = 2.8 Hz, 1H, 3’-H), 
3.64 (d, J = 2.8 Hz, 2H, 1’-H2), 7.43 (dd, J = J’ = 8.0 Hz, 1H, 5-H), 7.54 (dm, J = 8.0 
Hz, 1H), 7.58 (dm, J = 8.0 Hz, 1H) (4-H, 6-H), 7.68 (m, 1H, 2-H); 13C NMR (100.6 
MHz, CDCl3) δ 24.6 (CH2, C1’),  71.9 (CH, C3’), 80.3 (C, C2’), 112.8 (C, C1), 118.8 
(C, CN), 129.4 (CH), 130.7 (CH), 131.5 (CH), 132.5 (CH) (phenylene CH), 137.7 (C, 
C3); HRMS (ESI), calcd for (C10H7N + H+) 142.0651, found 142.0653. 
 
4.1.54. 4-(2-Propynyl)benzonitrile 65 
It was prepared as described for 64. From 62 (642 mg, 3.01 mmol) and AgOTf [(80 mg, 
0.31 mmol) × 2], a crude (548 mg) was obtained and purified through column 
chromatography (4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On 
elution with hexane / EtOAc 80:20, alkyne 65 (346 mg, 81% yield) was isolated as a 
white solid; Rf 0.76 (hexane / EtOAc 8:2), mp 8789 ºC; IR (ATR) v 3254 ({CH), 
2230 (C{N, C{C) cm1; 1H NMR (400 MHz, CDCl3) δ 2.25 (t, J = 2.8 Hz, 1H, 3’-H), 
3.67 (d, J = 2.8 Hz, 2H, 1’-H2), 7.48 [dm, J = 8.8 Hz, 2H, 3(5)-H], 7.62 [dm, J = 8.8 Hz, 
2H, 2(6)-H]; 13C NMR (100.6 MHz, CDCl3) δ 25.2 (CH2, C1’), 71.9 (CH, C3’), 80.2 
(C, C2’), 111.0 (C, C1), 118.9 (C, CN), 128.8 [2CH, C3(5)], 132.5 [2CH, C2(6)], 141.7 
(C, C4); HRMS (ESI), calcd for (C10H7N + H+) 142.0651, found 142.0647. 
 
4.1.55. 4-(2-Propynyl)phenylacetonitrile 66 
It was prepared as described for 64. From 63 (2.50 g, 11.0 mmol) and AgOTf (280 mg, 
1.09 mmol) × 2], a crude (1.79 g) was obtained and purified through column 
chromatography (4060 µm silica gel, hexane / EtOAc mixtures, gradient elution). On 
elution with hexane / EtOAc 95:5, alkyne 66 (1.31 g, 77% yield) was isolated as a white 
solid; Rf 0.41 (hexane / EtOAc 8:2), mp 58ºC; IR (ATR) v 3262 ({CH), 2254 
(C{N, C{C) cm1; 1H NMR (400 MHz, CDCl3) δ 2.19 (t, J = 2.8 Hz, 1H, 3’-H), 3.57 
(br s, 2H, 1’-H2), 3.69 (s, 2H, 1CH2CN), 7.27 (br d, J = 8.0 Hz, 2H), 7.36 (br d, J = 
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8.0 Hz, 2H) (PhCH); 13C NMR (100.6 MHz, CDCl3) δ 23.2 (CH2, 1CH2CN), 24.4 
(CH2, C1’), 70.8 (CH, C3’), 81.4 (C, C2’), 117.8 (C, CN), 128.1 (2CH), 128.6 (2CH) 
(PhCH), 128.3 (C, PhC1), 136.1 (C, PhC4); HRMS (ESI), calcd for (C11H9N + H+) 
156.0808, found 156.0808. 
 
4.1.56. 3-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzonitrile 67 
It was prepared as described for 9. From iodomethane (0.30 mL, 0.68 g, 4.82 mmol), 
NaN3 (342 mg, 5.26 mmol), Na2CO3 (1.39 g, 13.1 mmol), ascorbic acid (616 mg, 3.50 
mmol), CuSO4·5H2O (436 mg, 1.75 mmol), and alkyne 64 (618 mg, 4.38 mmol), 
compound 67 (823 mg, 95% yield) was obtained as a yellowish solid; Rf 0.64 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 8587 ºC; IR (ATR) v 2229 (C{N) cm1; 
1H NMR (400 MHz, CDCl3) δ 4.05 (s, 3H, 1’CH3), 4.09 (br s, 2H, 3CH2), 7.25 (s, 
1H, 5’-H), 7.39 (dd, J = J’ = 8.0 Hz, 1H, 5-H), 7.487.53 (complex signal, 3H, 2-H, 4-
H, 6-H); 13C NMR (100.6 MHz, CDCl3) δ 31.7 (CH3, 3CH3), 36.8 (CH2, 1’CH2), 
112.7 (C, C1), 118.8 (C, CN), 122.6 (CH, C5’), 129.5 (CH), 130.4 (CH), 132.2 (CH), 
133.4 (CH) (phenylene CH), 140.7 (C, C3), 146.1 (C, C4’); HRMS (ESI), calcd for 
(C11H10N4 + H+) 199.0978, found 199.0980. 
 
4.1.57. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzonitrile 68 
It was prepared as described for 9. From iodomethane (0.17 mL, 0.38 g, 2.70 mmol), 
NaN3 (191 mg, 2.94 mmol), Na2CO3 (779 mg, 7.35 mmol), ascorbic acid (350 mg, 1.99 
mmol), CuSO4·5H2O (250 mg, 1.00 mmol), and alkyne 65 (346 mg, 2.45 mmol), 
compound 68 (459 mg, 95% yield) was obtained as a white solid; Rf 0.63 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 116118 ºC; IR (ATR) v 2227 (C{N) cm1; 
1H NMR (400 MHz, CDCl3) δ 4.05 (s, 3H, 1’CH3), 4.12 (br s, 2H, 4CH2), 7.23 (s, 
1H, 5’-H), 7.36 [dm, J = 8.4 Hz, 2H, 3(5)-H], 7.57 [dm, J = 8.4 Hz, 2H, 2(6)-H]; 13C 
NMR (100.6 MHz, CDCl3) δ 32.3 (CH2, 4CH2), 36.8 (CH3, 1’CH3), 110.6 (C, C1), 
118.9 (C, CN), 122.6 (CH, C5’), 129.6 [2CH, C3(5)], 132.5 [2CH, C2(6)], 144.8 (C, 
C4), 146.1 (C, C4’); HRMS (ESI), calcd for (C11H10N4 + H+) 199.0978, found 
199.0978. 
 
4.1.58. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]phenylacetonitrile 69 
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It was prepared as described for 9. From iodomethane (0.58 mL, 1.32 g, 9.32 mmol), 
NaN3 (660 mg, 10.2 mmol), Na2CO3 (2.69 g, 25.4 mmol), ascorbic acid (1.19 g, 6.76 
mmol), CuSO4·5H2O (840 mg, 3.36 mmol), and alkyne 66 (1.31 g, 8.45 mmol), 
compound 69 (1.60 g, 89% yield) was obtained as a yellowish solid; Rf 0.93 (CH2Cl2 / 
MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 8688 ºC; IR (ATR) v 2241 (C{N) cm1; 
1H NMR (400 MHz, CDCl3) δ 3.71 (s, 2H, 1CH2CN), 4.02 (s, 3H, 1’CH3), 4.06 (s, 
2H, 4CH2), 7.21 (s, 1H, 5’-H), 7.237.30 (complex signal, 4H, PhCH); 13C NMR 
(100.6 MHz, CDCl3) δ 23.1 (CH2, 1CH2CN), 31.6 (CH2, 4CH2), 36.4 (CH3, 
1’CH3), 117.8 (C, CN), 122.3 (CH, C5’), 128.0 (C, PhC1), 128.1 (2CH), 129.2 
(2CH) (PhCH), 139.0 (C, PhC4), 147.1 (C, C4’); HRMS (ESI), calcd for (C12H12N4 + 
H+) 213.1135, found 213.1135. 
 
4.1.59. 3-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 70 
A solution of nitrile 67 (739 mg, 3.73 mmol) in anhydrous THF (30 mL) was cooled to 
0 ºC and treated dropwise with LiAlH4 (4 M solution in Et2O, 2.98 mL, 11.9 mmol). 
The reaction mixture was stirred under reflux for 2 h, cooled to 0 ºC, treated 
portionwise with 1 N NaOH (100 mL), diluted with H2O (100 mL), and extracted with 
EtOAc (3 × 100 mL). The combined organic extracts were dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford amine 70 (368 mg, 49% 
yield) as a yellow oil; Rf 0.28 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
70·HCl: yellowish solid, mp 119121 ºC; IR (ATR) v 34002300 (max at 3303, 3077, 
2908, 2870, 2356, 2322, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 4.14 (s, 
2H, 3CH2), 4.296 (s, 3H, 1’CH3), 4.302 (s, 2H, 1CH2N), 4.95 (s, +NH3), 7.387.52 
(complex signal, 4H, phenylene CH), 8.39 (s, 1H, 5’-H); 13C NMR (100.6 MHz, 
CD3OD) δ 30.2 (CH2, 3CH2), 39.8 (CH3, 1’CH3), 44.1 (CH2, 1CH2N), 129.1 (CH), 
129.2 (CH), 130.7 (2CH), 131.0 (CH) (phenylene CH, C5’), 135.3 (C), 138.2 (C) (C1, 
C3), 144.9 (C, C4’); HRMS (ESI), calcd for (C11H14N4 + H+) 203.1291, found 
203.1297. 
 
4.1.60. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 71 
It was prepared as described for 70. From nitrile 68 (310 mg, 1.56 mmol) and LiAlH4 (4 
M solution in Et2O, 1.18 mL, 4.72 mmol), amine 71 (254 mg, 81% yield) was obtained 
as a yellow oil; Rf 0.27 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
 49 
71·HCl: yellowish sticky solid, IR (ATR) v 34002500 (max at 3386, 2931, 2810, 
2536, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 4.11 (s, 2H, 4CH2), 4.22 
(s, 3H, 1’CH3), 4.90 (s, 1CH2N, +NH3), 7.38 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 
Hz, 2H) (phenylene CH), 8.16 (s, 1H, 5’-H); 13C NMR (100.6 MHz, CD3OD) δ 30.6 
(CH2, 4CH2), 38.9 (CH3, 1’CH3), 43.9 (CH2, 1CH2N),  127.7 (CH, C5’), 130.6 
(2CH), 130.7 (2CH) (phenylene CH), 133.4 (C), 139.3 (C) (C1, C4), 145.8 (C, C4’); 
HRMS (ESI), calcd for (C11H14N4 + H+) 203.1291, found 203.1292. 
 
4.1.61. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]phenethylamine 72 
A suspension of nitrile 69 (1.60 g, 7.54 mmol) and Raney-Ni (2.02 g, wet) in 7 N 
methanolic NH3 (32 mL) was hydrogenated by bubbling H2 overnight. The resulting 
mixture was filtered and the cake was washed with MeOH ( 2 × 15 mL). The combined 
filtrates were concentrated under reduced pressure to afford amine 72 (1.70 g, 
quantitative yield) as an oily residue; Rf 0.17 (CH2Cl2 / MeOH / 50% aq. NH4OH 
9.5:0.5:0.05). 
72·HCl: yellow solid, mp 158−160 ºC; IR (ATR) v 34002500 (max at 3390, 3331, 
3254, 2994, 2970, 2727, 2627, 2573, +NH and CH) cm1; 1H NMR (400 MHz, 
CD3OD) δ 2.93 (t, J = 7.6 Hz, 2H, 1CH2CH2N), 3.15 (t, J = 7.6 Hz, 2H, 
1CH2CH2N), 4.04 (s, 2H, 4CH2), 4.07 (s, 3H, 1’CH3), 4.86 (s, +NH3), 7.187.27 
(complex signal, 4H, PhCH), 7.73 (s, 1H, 5’-H); 13C NMR (100.6 MHz, CD3OD) δ 
31.9 (CH2, 4CH2), 34.1 (CH2, 1CH2CH2N), 37.2 (CH3, 1’CH3), 42.0 (CH2, 
1CH2CH2N),  125.0 (CH, C5’), 130.1 (2CH), 130.3 (2CH) (PhCH), 136.1 (C, 
PhC1), 139.3 (C, PhC4), 148.1 (C, C4’); HRMS (ESI), calcd for (C12H16N4 + H+) 
217.1448, found 217.1450. 
 
4.1.62. N-(tert-Butoxycarbonyl)-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 
73 
To a solution of 70 (352 mg, 1.74 mmol) in anhydrous THF (6 mL), a solution of di-
tert-butyl dicarbonate (380 mg, 1.74 mmol) in anhydrous THF (2 mL) was added at 0 
ºC. The reaction mixture was stirred at rt for 3 h and evaporated under reduced pressure. 
The resulting residue was washed with pentane (3 × 10 mL) and dried under vacuum, to 
afford 73 (520 mg, quantitative yield) as a yellow oil; Rf 0.85 (CH2Cl2 / MeOH / 50% 
aq. NH4OH 9.5:0.5:0.05); IR (ATR) v 3341 (NH), 1697 (C=O) cm1; 1H NMR (400 
 50 
MHz, CDCl3) δ 1.55 [s, 9H, C(CH3)3], 4.12 (s, 3H, 1’CH3), 4.16 (s, 2H, 3CH2), 4.38 
(d, J = 5.6 Hz, 2H, 1CH2N), 4.97 (br s, 1H, NHBoc), 7.227.27 (complex signal, 
3H), 7.337.38 (overlapped signal, 2H) (phenylene CH, 5’-H); 13C NMR (100.6 MHz, 
CDCl3) δ 28.5 [3CH3, C(CH3)3], 32.3 (CH2, 3CH2), 36.7 (CH3, 1’CH3), 44.7 (CH2, 
1CH2N), 79.6 [C, C(CH3)3], 122.6 (CH, C5’), 125.7 (CH), 127.8 (2CH), 129.0 (CH) 
(phenylene CH), 139.4 (C), 139.6 (C) (C1, C3), 147.8 (C, C4’), 156.0 (C, NCOO); 
HRMS (ESI), calcd for (C16H22N4O2 + H+) 303.1816, found 303.1812. 
 
4.1.63. N-(tert-Butoxycarbonyl)-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 
74 
It was prepared as described for 73. From 71 (90 mg, 0.45 mmol) and di-tert-butyl 
dicarbonate (98 mg, 0.45 mmol), 74 (133 mg, quantitative yield) was obtained as a 
beige solid; Rf 0.78 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
The analytical sample of 74 was obtained by filtration of a dichloromethane solution 
through a PTFE filter (0.2 µm), evaporation of the filtrate under reduced pressure and 
washing of the resulting solid with pentane (3 × 2 mL); IR (ATR) v 3382 (NH), 1690 
(C=O) cm1; 1H NMR (400 MHz, CDCl3) δ 1.44 [s, 9H, C(CH3)3], 4.00 (s, 3H, 
1’CH3), 4.04 (s, 2H, 4CH2), 4.26 (d, J = 5.6 Hz, 2H, 1CH2N), 4.86 (br s, 1H, 
NHBoc), 7.13 (s, 1H, 5’-H), 7.20 (complex signal, 4H, phenylene CH); 13C NMR 
(100.6 MHz, CDCl3) δ 28.5 [3CH3, C(CH3)3], 32.0 (CH2, 4CH2), 36.7 (CH3, 1’CH3), 
44.4 (CH2, 1CH2N), 79.6 [C, C(CH3)3],  122.5 (CH, C5’), 127.8 (2CH), 129.0 (2CH) 
(phenylene CH), 137.3 (C), 138.3 (C) (C1, C4), 148.0 (C, C4’), 156.0 (C, NCOO); 
HRMS (ESI), calcd for (C16H22N4O2 + H+) 303.1816, found 303.1817. 
 
4.1.64. N-(tert-Butoxycarbonyl)-4-[(1-methyl-1H-1,2,3-triazol-4-
yl)methyl]phenethylamine 75 
It was prepared as described for 73. From 72 (1.65 g, 7.63 mmol) and di-tert-butyl 
dicarbonate (1.67 g, 7.65 mmol), 75 (2.34 g, quantitative yield) was obtained as a solid; 
Rf 0.91 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); mp 92−94 °C; IR (ATR) v 
3358 (NH), 1677 (C=O) cm1; 1H NMR (400 MHz, CDCl3) δ 1.42 [s, 9H, C(CH3)3], 
2.76 (t, J = 6.8 Hz, 2H, 1CH2CH2N), 3.35 (dt, J = J’ = 6.8 Hz, 2H, 1CH2CH2N), 
4.02 (s, 3H, 1’CH3), 4.05 (s, 2H, 4CH2), 4.54 (br s, 1H, NHBoc), 7.12 (br d, J = 8.0 
Hz, 2H), 7.19 (br d, J = 8.0 Hz, 2H) (PhCH), 7.16 (s, 1H, 5’-H); 13C NMR (100.6 
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MHz, CDCl3) δ 28.4 [3CH3, C(CH3)3], 31.8 (CH2, 4CH2), 35.8 (CH2, 
1CH2CH2N), 36.5 (CH3, 1’CH3), 41.8 (CH2, 1CH2CH2N), 79.2 [C, C(CH3)3],  
122.3 (CH, C5’), 128.9 (2CH), 129.0 (2CH) (PhCH), 137.16 (C), 137.23 (C) (PhC1, 
PhC4), 147.9 (C, C4’), 155.8 (C, NCOO); HRMS (ESI), calcd for (C17H24N4O2 + H+) 
317.1972, found 317.1982. 
 
4.1.65. N-(tert-Butoxycarbonyl)-N-methyl-3-[(1-methyl-1H-1,2,3-triazol-4-
yl)methyl]benzylamine 76 
It was prepared as described for 17. From compound 73 (480 mg, 1.59 mmol), NaH 
(60% supension in mineral oil, 96 mg, 2.40 mmol), and iodomethane (0.11 mL, 251 mg, 
1.77 mmol), stirring at 60 ºC for 2 h, treating again with NaH (60% supension in 
mineral oil, 96 mg, 2.40 mmol), and iodomethane (0.11 mL, 251 mg, 1.77 mmol) and 
stirring at 60 ºC for an additional 2 h, compound 76 (422 mg, 84% yield) was obtained 
as an orange oil; Rf 0.85 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); IR (ATR) v 
1686 (C=O) cm1; 1H NMR (400 MHz, CDCl3) δ 1.48 [br s, 9H, C(CH3)3], 2.82 (br s, 
3H, NCH3), 4.04 (s, 3H, 1’CH3), 4.08 (s, 2H, 3CH2), 4.40 (br s, 2H, 1CH2N), 
7.087.19 (complex signal), 7.257.30 (complex signal) (5H, phenylene CH, 5’-H); 13C 
NMR (100.6 MHz, CDCl3) δ 28.6 [3CH3, C(CH3)3], 32.3 (CH2, 3CH2), 34.1 (CH3, 
NCH3), 36.7 (CH3, 1’CH3), 52.0 (br CH2), 52.7 (br CH2) (1CH2N), 79.8 [C, 
C(CH3)], 122.5 (CH, C5’), 125.6 (br CH), 125.8 (br CH), 127.7 (CH), 127.8 (br CH), 
128.9 (CH) (phenylene CH), 138.6 (C), 139.5 (C) (C1, C3), 147.9 (br C, C4’), 156.4 (br 
C, NCOO); HRMS (ESI), calcd for (C17H24N4O2 + H+) 317.1972, found 317.1970. 
 
4.1.66. N-(tert-Butoxycarbonyl)-N-methyl-4-[(1-methyl-1H-1,2,3-triazol-4-
yl)methyl]benzylamine 77 
It was prepared as described for 17. From compound 74 (140 mg, 0.46 mmol), NaH 
(60% supension in mineral oil, 28 mg, 0.70 mmol), and iodomethane (0.03 mL, 68 mg, 
0.48 mmol), stirring at 60 ºC for 2 h, treating again with NaH (60% supension in 
mineral oil, 28 mg, 0.70 mmol), and iodomethane (0.03 mL, 68 mg, 0.48 mmol) and 
stirring at 60 ºC for an additional 2 h, compound 77 (120 mg, 83% yield) was obtained 
as a brown oil; Rf 0.56 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05); IR (ATR) v 
1686 (C=O) cm1; 1H NMR (400 MHz, CDCl3) δ 1.46 [br s, 9H, C(CH3)3], 2.79 (br s, 
3H, NCH3), 4.01 (s, 3H, 1’CH3), 4.05 (s, 2H, 4CH2), 4.37 (br s, 2H, 1CH2N), 
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7.14 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H) (phenylene CH), 7.20 (s, 1H, 5’-H); 
13C NMR (100.6 MHz, CDCl3) δ 28.6 [3CH3, C(CH3)3], 32.0 (CH2, 4CH2), 34.0 (CH3, 
NCH3), 36.7 (CH3, 1’CH3), 51.7 (br CH2), 52.4 (br CH2) (1CH2N), 79.8 [C, 
C(CH3)3], 122.5 (CH, C5’), 127.8 (br CH), 128.0 (br CH), 128.9 (CH), 129.0 (CH) 
(phenylene CH), 136.4 (C), 138.2 (C) (C1, C4), 148.0 (C, C4’), 155.9 (br C, NCOO); 
HRMS (ESI), calcd for (C17H24N4O2 + H+) 317.1972, found 317.1965. 
 
4.1.67. N-Methyl-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 79 
It was prepared as described for 25. From 76 (384 mg, 1.21 mmol) and H3PO4 (85% 
purity, 2.15 mL, 18.6 mmol), amine 79 (242 mg, quantitative yield) was obtained as an 
orange oil; Rf 0.30 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
79·HCl: sticky solid, IR (ATR) v 34002400 (max at 3374, 3116, 3074, 2956, 2778, 
2699, 2542, 2417, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 2.73 (s, 3H, 
NCH3), 4.21 (s, 2H, 3CH2), 4.32 (s, 3H, 1’CH3), 4.33 (s, 2H, 1CH2N), 4.99 (s, 
+NH2), 7.427.52 (complex signal, 3H, 4-H, 5-H, 6-H), 7.55 (br s, 1H, 2-H), 8.47 (s, 
1H, 5’-H); 13C NMR (100.6 MHz, CD3OD) δ 30.0 (CH2, 3CH2), 33.2 (CH3, NCH3), 
40.0 (CH3, 1’CH3), 53.3 (CH2, 1CH2N), 129.5 (CH), 130.3 (CH), 131.1 (CH), 131.2 
(CH), 131.5 (CH) (phenylene CH, C5’), 133.6 (C, C1), 138.0 (C, C3), 144.5 (C, C4’); 
HRMS (ESI), calcd for (C12H16N4 + H+): 217.1448, found 217.1446. 
 
4.1.68. N-Methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 80 
It was prepared as described for 25. From 77 (237 mg, 0.75 mmol) and H3PO4 (85% 
purity, 1.29 mL, 11.2 mmol), amine 80 (156 mg, 96% yield) was obtained as an orange 
oil; Rf 0.24 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
80·HCl: sticky solid, IR (ATR) v 34002400 (max at 3339, 3085, 2931, 2744, 2708, 
2547, 2415, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 2.71 (s, 3H, 
NCH3), 4.19 (s, 2H, 4CH2), 4.23 (s, 3H, 1’ CH3), 4.24 (s, 2H, 1CH2N), 4.90 (s, 
+NH2), 7.42 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H) (phenylene CH), 8.20 (s, 1H, 
5’-H); 13C NMR (100.6 MHz, CD3OD) δ 30.6 (CH2, 4CH2), 33.1 (CH3, NCH3), 39.0 
(CH3, 1’CH3), 53.1 (CH2, 1CH2N), 127.9 (CH, C5’), 130.7 (2CH), 131.62 (2CH) 
(phenylene CH), 131.56 (C, C1), 139.7 (C, C4), 145.6 (C, C4’); HRMS (ESI), calcd for 
(C12H16N4 + H+) 217.1448, found 217.1448. 
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4.1.69. N-Methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]phenethylamine 81 
To a suspension of LiAlH4 (118 mg, 3.11 mmol) in dry THF (4 mL), a solution of 75 
(165 mg, 0.52 mmol) in dry THF (4 mL) was added dropwise at 0 ºC. The reaction 
mixture was stirred at reflux for 72 h, cooled to 0 ºC, diluted with 1 N NaOH  (20 mL), 
and extracted with CH2Cl2 (3 × 15 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford an oily 
residue (169 mg), which was purified through column chromatography (40‒60 μm 
silica gel,  CH2Cl2 / MeOH / 50% aq. NH4OH mixtures, gradient elution). On elution 
with CH2Cl2 / MeOH / 50% aq. NH4OH 95:5:0.2, amine 81 (53 mg, 44% yield) was 
isolated as a yellow oil; Rf 0.16 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
81·HCl: yellowish solid, mp 149151 ºC; IR (ATR) v 34002400 (max at 3395, 3118, 
2938, 2771, 2450, +NH and CH) cm1; 1H NMR (400 MHz, CD3OD) δ 2.71 (s, 3H, 
NCH3), 2.97 (t, J = 7.2 Hz, 2H, 1CH2CH2N), 3.23 (t, J = 7.2 Hz, 2H, 
1CH2CH2N), 4.06 (s, 2H, 4CH2), 4.09 (s, 3H, 1’CH3), 4.86 (s, +NH2), 7.24 (dm, J 
= 8.8 Hz, 2H), 7.27 (dm, J = 8.8 Hz, 2H) (PhCH), 7.81 (s, 1H, 5’-H); 13C NMR (100.6 
MHz, CD3OD) δ 31.7 (CH2, 4CH2), 32.9 (CH2, 1CH2CH2N), 33.7 (CH3, NCH3), 
37.5 (CH3, 1’CH3), 51.4 (CH2, 1CH2CH2N), 125.5 (CH, C5’), 130.1 (2CH), 130.4 
(2CH) (PhCH), 136.0 (C), 139.0 (C) (PhC1, PhC4), 147.7 (C, C4’); HRMS (ESI), 
calcd for (C13H18N4 + H+) 231.1604, found 231.1605. 
 
4.1.70. N-Methyl-N-{3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzyl}-N-
propargylamine 82 
It was prepared as described for 31. From amine 79 (236 mg, 1.09 mmol), Cs2CO3 (354 
mg, 1.09 mmol), and propargyl bromide (80% solution in toluene, 0.16 mL, 1.08 
mmol), and stirring at at 0 °C for 30 min and at rt for an additional 3 h, propargylamine 
82 (180 mg, 66% yield) was obtained as a yellow oil, without the need of 
chromatographic purification; Rf 0.66 (CH2Cl2 / MeOH / 50% aq. NH4OH 9.5:0.5:0.05). 
82·HCl: sticky solid; IR (ATR) v 34002400 (max at 3389, 3191, 3023, 2930, 2491, 
+NH, {CH, and CH), 2122 (C{C) cm1; 1H NMR (400 MHz, CD3OD) δ 2.94 (s, 
3H, NCH3), 3.47 (t, J = 2.8 Hz, 1H, propargyl CH), 4.08 (br s, 2H, propargyl CH2), 
4.26 (s, 3H, 1’CH3), 4.30 (s, 2H, 3CH2), 4.47 (br signal, 2H, 1CH2N), 5.04 (s, 
+NH), 7.487.56 (complex signal, 3H, 4-H, 5-H, 6-H), 7.61 (br s, 1H, 2-H), 8.33 (s, 1H, 
5’-H); 13C NMR (100.6 MHz, CD3OD) δ 30.5 (CH2, 3CH2), 39.3 (CH3, 1’CH3), 40.1 
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(CH3, NCH3), 45.4 (CH2, propargyl CH2), 59.4 (CH2, 1CH2N), 72.8 (C, propargyl 
C), 81.9 (CH, propargyl CH), 128.4 (CH, C5’), 131.0 (CH), 131.2 (CH + C), 131.8 
(CH), 132.6 (CH) (C1, phenylene CH), 139.2 (C, C3), 145.2 (C, C4’); HRMS (ESI), 
calcd for (C15H18N4 + H+) 255.1604, found 255.1600. 
 
4.1.71. N-Methyl-N-{4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzyl}-N-
propargylamine 83 
It was prepared as described for 31. From amine 80 (131 mg, 0.61 mmol), Cs2CO3 (0.20 
g, 0.61 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), 
and stirring at at 0 °C for 3.5 h, an orange oily residue (122 mg) was obtained and 
purified through column chromatography (4060 µm silica gel, CH2Cl2 / 50% aq. 
NH4OH 100:0.2), to afford propargylamine 83 (48 mg, 40% yield) as a yellow oil; Rf 
0.67 (CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
83·HCl: mp 156158 ºC; IR (ATR) v 34002400 (max at 3178, 3095, 2923, 2692, 
2501, 2418, +NH, {CH, and CH), 2120 (C{C) cm1; 1H NMR (400 MHz, CD3OD) 
δ 2.92 (s, 3H, NCH3), 3.47 (t, J = 2.8 Hz, 1H, propargyl CH), 4.05 (br signal, 2H, 
propargyl CH2), 4.19 (s, 3H, 1’CH3), 4.22 (s, 2H, 4CH2), 4.41 (br signal, 2H, 
1CH2N), 4.86 (s, +NH), 7.44 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H) (phenylene 
CH), 8.10 (s, 1H, 5’-H); 13C NMR (100.6 MHz, CD3OD) δ 30.6 (CH2, 4CH2), 39.0 
(CH3, 1’CH3), 40.1 (CH3, NCH3), 45.4 (CH2, propargyl CH2), 59.3 (CH2, 1CH2N), 
72.8 (C, propargyl C), 81.9 (CH, propargyl CH), 128.0 (CH, C5’), 129.4 (C, C1), 130.9 
(2CH), 132.9 (2CH) (phenylene CH), 140.5 (C, C4), 145.5 (C, C4’); HRMS (ESI), 
calcd for (C15H18N4 + H+) 255.1604, found 255.1599. 
 
4.1.72. N-methyl-N-{4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]phenethyl}-N-
propargylamine 84 
It was prepared as described for 31. From amine 81 (30 mg, 0.13 mmol), Cs2CO3 (42 
mg, 0.13 mmol), and propargyl bromide (80% solution in toluene, 0.02 mL, 0.13 
mmol), and stirring at 0 °C for 30 min and at rt for an additional 3 h, an oily residue (48 
mg) was obtained and purified through column chromatography (4060 µm silica gel, 
CH2Cl2), to afford propargylamine 84 (20 mg,  57% yield) as a yellow oil; Rf 0.55 
(CH2Cl2 / MeOH / 50% aq. NH4OH 9:1:0.05). 
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84·HCl: sticky solid; IR (ATR) v 35002400 (max at 3413, 3358, 3213, 3068, 2944, 
2496, +NH, {CH, and CH), 2144 (C{C) cm1; 1H NMR (400 MHz, CD3OD) δ 3.02 
(s, 3H, NCH3), 3.06 (t, J = 6.8 Hz, 2H, 1CH2CH2N), 3.41 (m, 1H, propargyl CH), 
3.48 (br signal, 2H, 1CH2CH2N), 4.09 (s, 2H, propargyl CH2), 4.12 (s, 3H, 
1’CH3), 4.18 (s, 2H, 4CH2), 4.86 (s, +NH), 7.28 (complex signal, 4H, PhCH), 7.89 
(s, 1H, 5’-H); 13C NMR (100.6 MHz, CD3OD) δ 31.1 (CH2), 31.4 (CH2) (4CH2, 
1CH2CH2N), 37.9 (CH3, 1’CH3), 40.7 (CH3, NCH3), 46.3 (CH2, propargyl CH2), 
57.5 (CH2, 1CH2CH2N), 72.8 (C, propargyl C), 81.5 (CH, propargyl CH), 126.1 
(CH, C5’), 130.3 (2CH), 130.4 (2CH) (PhCH), 135.7 (C), 138.7 (C) (PhC1, PhC4), 
147.3 (C, C4’); HRMS (ESI), calcd for (C16H20N4 + H+) 269.1761, found 269.1760. 
 
4.2. Biological assays 
4.2.1. Inhibition of hrMAO-A and hrMAO-B 
The activity of hrMAO-A and hrMAO-B (Sigma-Aldrich, Madrid, Spain) was 
determined using Amplex UltraRed fluorometric coupled method. For both MAO 
isoforms, tyramine hydrochloride was used as substrate and enzymatic assays were 
performed in 96-well black opaque microplates (OptiPlate-96F, PerkinElmer) in a final 
volume of 200 μL. Serial dilutions of each inhibitor were pre-incubated with either 0.36 
U/mL hrMAO A or 0.0675 U/mL hrMAO B for 30 min at 37 ºC. Enzymatic reactions 
were started upon the addition of 100 μL of a mixture solution containing 1 mM 
tyramine, 0.04 U/mL horseradish peroxidase (HRP) and 25 mM Amplex UltraRed® 
reagent in 0.25 mM sodium phosphate (pH 7.4) as final concentrations. The 
fluorescence production of resorufin was measured for at least 30 min at 530/590 nm in 
a spectrophotometric plate reader (FluoStar OPTIMA, BM G Labtech). The enzymatic 
activity in the absence of compound was used to determine 100% enzyme activity. The 
potential capacity of the compounds to interfere with the fluorescence generated in the 
reaction was determined by adding the compounds to solutions in the absence of MAO. 
From dose-response curves, IC50 values were accordingly calculated using the 
GraphPad ‘PRISM’ software (version 5.0). Data are expressed as mean ± SEM of at 
least three different experiments performed in duplicate. Clorgyline and R-deprenyl 
(Sigma-Aldrich) were used as reference compounds. 
 
4.2.2. Reversibility of hrMAO-B inhibition 
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To study the reversibility of the inhibition of hrMAO-B by compound 33, 100-fold 
enzyme concentration was inhibited by 200 nM L-deprenyl or 50 nM 33 (10-fold IC50 
values) for 1 h at 37 ºC. Following pre-incubation times, enzyme solution was rapidly 
diluted (100-fold) in a mix solution containing 1 mM p-tyramine, HRP and Amplex 
UltraRed® reagent in 50 mM phosphate buffer pH 7.4. Next, hrMAO-B activity was 
followed at 530/590 nm for 40 min. 
 
 
4.2.3. Time-dependent inhibition of hrMAO-B 
To investigate the time-dependent inhibition of hrMAO-B activity by compound 33, the 
enzyme was inhibited by 10 μM 33 for at different pre-incubation times (0-360 min). At 
the end of each pre-incubation, activity was measured as previously described and 
plotted as percentage of control samples versus pre-incubation time. 
 
 
4.2.4. Determination of brain permeability: PAMPA-BBB assay 
The in vitro permeability (Pe) of the novel 1,2,3-triazole-based compounds and fourteen 
known drugs (Table 2) through lipid extract of porcine brain membrane was determined 
by using a parallel artificial membrane permeation assay82 using a mixture PBS:EtOH 
70:30. Assay validation was made by comparison of the experimental Pe values of the 
known drugs with their reported values, which showed a good correlation: Pe (exp) = 
1.003 Pe (lit) – 0.783 (R2 = 0.93). From this equation and the limits established by Di et 
al. for BBB permeation,82 three ranges of permeability were established: compounds of 
high BBB permeation  (CNS+): Pe (10-6 cm s-1) > 5.18; compounds of low BBB 
permeation  (CNS‒): Pe (10-6 cm s-1) < 2.06; compounds of uncertain BBB permeation  
(CNS±): and  5.18 > Pe (10-6 cm s-1) > 2.06. 
 
 
Table 2. Reported and experimental permeability values (Pe 10–6 cm s–1) of 14 
commercial drugs used for the PAMPA-BBB assay validation 
 
 
Compound 
 
Literature  
valuea 
 
Experimental  
valueb 
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Cimetidine 0.0 0.70 ± 0.03 
Lomefloxacin 0.0 0.78 ± 0.04 
Norfloxacin 0.1 0.90 ± 0.02 
Ofloxacin 0.8 0.98 ± 0.06 
Hydrocortisone 1.9 1.40 ± 0.05 
Piroxicam 2.5 1.93 ± 0.11 
Clonidine 5.3 6.50 ± 0.05 
Corticosterone 5.1 6.70 ± 0.10 
Imipramine 13 12.3 ± 0.1 
Promazine 8.8 13.8 ± 0.3 
Progesterone 9.3 16.8 ± 0.1 
Desipramine 12 17.8 ± 0.1 
Testosterone 17 24.0 ± 1.4 
Verapamil 16 28.1 ± 1.6 
a Taken from ref. [82]. 
b Values are expressed as the mean ± SD of three independent experiments. 
 
 
4.3. Docking studies 
The binding mode of selected 1,2,3-triazole derivatives was explored by means of 
docking calculations carried out with Glide, using an empirical scoring function 
calibrated on the basis of protein−ligand complexes.84 Docking was performed using the 
MAO-B X-ray structure of the complex with inhibitor 6 (PDB entry 4CRT)80 and 
deprenyl (PDB entry 2BYB),28 but no significant differences were found for the best 
ligand poses. The protocol defined in our previous studies was adopted here.39 Briefly, 
the docking volume was defined as the space covered by the binding cavity in MAO-B. 
Suitable restraints were introduced to keep the amine nitrogen of the proargylamine unit 
close to the position found for the corresponding atom in deprenyl and rasagiline (PDB 
entry 2BK4)79 in order to mimic the orientation after irreversible linkage with the FAD. 
Each compound was subjected to 100 docking runs. Whereas the protein was kept rigid, 
Glide accounts for the conformational flexibility of the ligand around rotatable bonds 
during docking calculations. The output docking modes were analyzed by visual 
inspection in conjunction with the docking scores. 
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